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Hypertrophic scarring is a poorly understood condition which affects the lives of 
millions of people around the world annually. Despite its common occurrence 
following burn injury, trauma or surgery the present treatments are of limited 
efficacy. Research over the past decade in the Cowin laboratory has identified 
Flightless (Flii), a highly conserved cytoskeletal protein, as a negative regulator of 
wound healing. Wounding leads to an increased expression of Flii, while Flii has 
been shown to inhibit cellular migration and proliferation. Reducing Flii in vivo 
leads to improved wound healing. The aim of this study was to investigate the role 
of Flii in the fibroproliferative process underlying hypertrophic scarring. 
 
Chapter three shows for the first time that Flii expression in increased in human 
burn and hypertrophic scar tissue. 
 
Chapter four details the development of a novel murine model of hypertrophic 
scarring. Previous animal models have focused on reproducing the clinical 
characteristics of the human hypertrophic scar, which often required significant 
derangement of the animal immune response. The novel model used bleomycin to 
stimulate the fibroproliferative process that underlies hypertrophic scarring. 
Results in this chapter use histology and immunohistochemistry to verify the 
bleomycin model as a valid model of hypertrophic scarring. 
xiv  
Chapter five uses the bleomycin mode to demonstrate that Flii is a key determinant 
of the extent of fibroproliferation that underlies hypertrophic scarring. Increasing 
Flii genetically in this animal model leads to increased dermal thickening and 
increases in key determinants of hypertrophic scarring, such as myofibroblasts, 
transforming growth factor -1 (TGF-1) and scar collagen composition. Decreasing 
Flii genetically causes a reduction in hypertrophic scarring using the same 
measures. Decreasing Flii using a monoclonal antibody therapy in the bleomycin 
model also led to a reduction in hypertrophic scarring, confirming Flii as a potential 
target for a novel therapy for hypertrophic scarring. 
 
Chapter six investigates potential mechanisms for the findings observed in previous 
chapters by using in vivo techniques. Focusing on the fibroblast, the key cell type in 
fibroproliferation, immunocytochemistry and cell migration assays, were used to 
show that decreasing Flii genetically or using a monoclonal antibody, reverses the 
fibroblast-myofibroblast phenotypic change that characterizes fibroproliferartive 
pathology. 
 
Flii appears to be a key determinant of the fibroproliferative process underlying 
hypertrophic scarring. This study uses human tissue, a novel small animal model 
and in vivo techniques to demonstrate this and identify Flii as a potential target for a 
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All multicellular organisms are equipped to repair damage to their outermost 
layer via the process known as wound healing. The normal wound healing process 
is a tightly orchestrated sequence involving numerous cell types, extracellular 
matrix components and signalling molecules (Singer & Clark, 1999). It balances 
several requirements, including prevention of infection; restoration of epithelial 
integrity; and approximation of normal skin structure and function (Bielefeld et 
al., 2013). 
 
In humans, the inevitable result of normal wound healing is the rapid interposition 
of scar tissue, which is eventually remodeled so that the disturbance to normal 
skin structure and function is minimized. However, there are a number of 
circumstances in which abnormal wound healing leads to pathology. These 
pathologies can arbitrarily be placed on a spectrum ranging from “under-healing” 
(chronic wounds, diabetic ulcers, skin blistering diseases) through to those 








Figure 1.1 The spectrum of wound healing pathology Schematic 
representation of the “spectrum “ of wound healing pathology, which ranges from 
pathology associated with impaired healing (e.g. chronic ulcers) to pathology 
associated with excessive healing (e.g. hypertrophic scarring). 
 
 
Wound healing pathologies represent an area of unmet clinical need. Chronic 
wounds are estimated to affect 443 000 Australians and cost the health system 
$2.6 billion annually (Wound Management Innovation CRC Annual Report). 
Excessive scarring occurs in greater than 70% of deep burns and carries a 
considerable burden of disease, includes disfigurement, pain, disability and 
psychological co-morbidity (Brown et al., 2008). Current therapies mainly focus 
on managing the end-stages of abnormal wound healing rather than preventing 
these complications from occurring (Franz et al., 2007). The majority of these 
treatments relies largely on anecdotal evidence and lack a strong evidence base 
for their efficacy or understanding of mechanisms of action (Mustoe et al., 2002; 
Robson et al., 2001). 
 
Across taxa, we see considerable diversity in how wound healing occurs. Most 






amphibians are able to regenerate an amputated appendage through the 
formation of a blastema (a mass of undifferentiated cells capable of regeneration) 
(Bielefeld et al., 2013). Even certain human tissues demonstrate regenerative 
healing. The adult liver may regenerate up to 70% of its mass without scarring, 
while gingiva also demonstrates scar free wound healing. The skin of the human 
foetus is capable of scar free wound healing until late in the third trimester 
(Gurtner et al., 2008). As the core components of the wound healing process are 
highly conserved across multicellular organisms, much attention has focused on 
elucidating key differences in specific cell populations and molecular pathways 
that influence the eventual outcome. If these are unveiled, it follows that this 
knowledge could be used to manipulate human wound healing (Gurtner et al., 
2008). 
 
This introduction will outline the current understanding of wound healing. It will 
then contextualize hypertrophic scarring the outcome of the dysregulation of this 
process. Flightless (Flii), a novel member of the gelsolin family of proteins will be 






1.2 Skin Biology 
 
Mammalian skin consists of two layers: the epidermis, a keratinized epithelial 
layer comprised of keratinocytes; and the dermis, a spongy dermal layer consisting 
mainly of collagen, as well as fibroblasts and skin appendages (Martin, 1997). The 
skin fulfills several vital functions. It is the body’s primary physical and immune 
barrier to trauma and infection. It is also vital for thermoregulation and gathering 
information about the external environment through touch, pain and temperature 
sensation (Alonso & Fuchs, 2006; Koster, 2009). 
 
Figure 1.2 Anatomy of the skin. Illustration of skin anatomy, demonstrating 












The epidermis is comprised of keratinocytes, which continually differentiate, 
divide and migrate towards the skin’s surface. It can be further divided into five 
layers depending on the stage of cell differentiation: stratum basale, stratum 
spinosum, stratum granulosum, stratum lucidum and stratum corneum (see 
Figure 1.3) (Alonso & Fuchs, 2006; Koster, 2009). 
 
The stratum basale is comprised of undifferentiated keratinoctyes, which are able 
to consistently renew their population. Cells of the next layer, the stratum 
spinosum maintain the structural integrity of the epithelium and produce keratin- 
1 and keratin-10. Cells in the stratum granulosum are characterized by the 
production of keratohyalin granules which contain histidine rich proteins and 
keratin (Kanitakis, 2002). The stratum lucidum, named for its translucent 
microscopic appearance, is comprised of 3-5 layers of dead keratinocytes and 
underlies the stratum corneum. It takes 14 days for a keratinocyte to reach the 
stratum corneum from its origin at the stratum basale. By this time the previously 
living keratinocytes are transformed into non-living corneocytes, whose cell 
membranes are replaced by a layer of ceramides, which covalently link to the 
cornified envelope and are integral to barrier function (Alonso & Fuchs, 2006). 
 
A range of keratinocyte junctions also contribute to barrier function, both 
structurally as well as by regulating cell proliferation and differentiation (Byrne 






which augment the barrier function of the stratum corneum. Gap junctions 
provide intercellular communication between keratinocytes, while a network of 
keratin and actin filaments maintain the three dimensional architecture of the 
epidermis. Stratum specific distribution of cadherin subtypes help to maintain the 
epidermis through differential adhesion between cells at different layers and 
adherens junctions are important in cell proliferation (Butnaru & Kanitakis, 2002; 
Byrne et al., 2003). 
 
 
The basement membrane separates the dermis from the epidermis and is 
comprised of a series of proteins that provide a connection between the two layers 
(McMillan et al., 2003). Its structural components include keratin monofilaments, 
outer and inner plaques of hemidesmosomes, plasma membrane, lamina lucida, 





















Figure 1.3 Diagrammatic representation of human skin. Diagrammatic 
representation of human skin illustrating epidermal layers and the basement 
membrane. Intercellular junctions comprised of tight junctions, adherens 








The dermis is the second layer of skin and varies in thickness from 0.3mm – 3mm. 
It is primarily comprised of elastic tissue, namely collagen, elastin and reticular 
fibres. The papillary dermis is the thin upper layer consisting of loosely arranged 
collagen fibres and elastin. The deeper reticular layer, which extends to the 
subcutaneous tissue, is composed of thick collagen fibres orientated parallel to the 
surface of the skin as well as a thicker elastic network, dermal appendages and 
neurovascular structures (Habif, 2004). Dermal collagen is predominately made 
of collagen-1 and collagen-3, which maintain structural integrity and strength of 
the skin. Also important are collagen-3, found in the basement membrane and 
blood vessels, and collagen-7 which is important in anchoring the dermis to the 
epidermis (Kanitakis, 2002). Mutations in collagen 7 lead to the skin blistering 
disease, epidermolysis bullosa (Dang & Murrell, 2008). 
 
Fibroblasts are spindle shaped cells that produce collagen. They are thought to 
have a key regulatory role in the wound healing process. Myofibroblasts are a 
contractile phenotype of the fibroblast which drive tissue repair through collagen 
production and by contracting the ECM (Bochaton-Piallat et al., 2016).Their 
dysfunction is thought to be central to the fibroproliferation that leads to 
hypertrophic scarring (Gurtner et al., 2008). Other cells found within the dermis 
include macrophages that function to scavenge dead cells or debris; and mast cells, 
located primarily around blood vessels, which manufacture and release histamine 






1.3 Wound Healing 
 
In order to understand hypertrophic scarring as an aberration of normal wound 
healing, it is important to understand the normal wound healing process. The 
chronology and components of normal wound healing have been well described, 
with events being divided into three arbitrary phases: inflammation, proliferation 
and remodelling (Singer & Clark, 1999). 
 
1.3.1 Haemostasis  
 
Following damage to the skin, the coagulation cascade is initiated within the first 
minute after injury. Platelets are activated and clump together to achieve 
haemostasis. Fibrin is then incorporated and a fibrin plug is formed (Grose & 
Werner, 2004). Within one to two hours post-injury various cytokines, growth 
factors, fibronectin and pro-inflammatory mediators are released, which initiate 
the inflammatory phase of wound healing (Singer & Clark, 1999). 
 
1.3.2 Inflammatory Phase 
 
 
Immune cells, namely neutrophils and macrophages, enter the wound by binding 
to integrins and becoming internalised through endothelial gaps. These cells 
accumulate within the wound and eliminate foreign material, dead tissue or 
microbes. At the same time, hypoxia within the wound stimulates keratinocyte 
migration and local fibroblast proliferation (Falanga, 2005). All cells produce 
further cytokines, growth factors and angiogenic factors, which lead to the 
accumulation of fibroblasts within the wound and in time, the initiation of the 






1.3.2 Proliferative Phase 
 
 
The proliferative phase generally lasts from 4 to 21 days. Keratinocytes, which 
are normally adherent to their adjacent cells via desmosomes and to the basement 
membrane via hemidesmosomes, take on a migratory phenotype. This involves 
hemidesmosome disassembly, dissolution of desmosomes and retraction of 
intracellular tonofilaments. At the same time lamellapodia and focal complexes 
develop (Santoro & Gaudino, 2005). 
 
Re-epithelialization occurs with the migration of keratinocytes from wound 
margins, across the fibrin and fibronectin matrix. In addition to migration, 
keratinocyte proliferation is increased, stimulated by various growth factors, 
integrins and metalloproteinases (Falanga, 2005). 
 
Fibroblasts and their contractile phenotype, myofibroblasts, produce collagen rich 
connective tissue, which replaces the provisional fibrin matrix to form granulation 
tissue, a new scaffold for cell migration (Figure 1.4). 
 
Granulation tissue is predominately comprised of collagen, particularly collagen- 
1 and collagen-3. Collagen-3 is produced in early wound healing before being 
replaced by collagen-1 (W. Liu et al., 2001). Collagen-4 is important in the 











Figure 1.4 The fibroblast (centre) and the proliferative phase of wound 
healing. Various growth factors and cytokines released in the inflammatory 
phase of wound healing lead to the migration of fibroblasts to the wound, which 
then proliferate, undergo phenotypic change to myofibroblasts and produce 
collagen (Werner & Grose, 2003)(Werner & Grose, 2003)(Werner & Grose, 
2003)(Werner and Grose 2003). 
 
 
1.3.3 Remodelling phase 
 
 
Once an abundant collagen matrix has been established, cells in the wound 
undergo apoptosis during the remodelling phase, which can last for up to two 
years and eventually results in an acellular and avascular scar. The remodelling 
phase involves both wound contraction and collagen remodelling. Wound 
contraction is brought about when fibroblasts assume a myofibroblast phenotype, 






matrix contraction (Bochaton-Piallat et al., 2016; Singer & Clark, 1999). At the 
same time, collagen-3 is degraded by matrix metalloproteinases (MMPs) and 
replaced by collagen-1. This collagen remodelling, combined with increased 
collagen cross linking, leads to increased scar tensile strength. 
 
This wound healing process is a tightly orchestrated sequence, which balances the 
synthesis and degradation of collagen in order to repair injury with as little 
disruption of normal skin architecture as possible. Hypertrophic scarring 
represents an aberration of normal wound healing where this balance is disrupted 
in favour of excess collagen production. 
 
1.4 The Myofibroblast 
 
First defined in the early 1970s, the myofibroblast was identified as the main cell 
type responsible for fibrotic pathology (Gabbiani et al., 1971). The classically 
recognised features of the myofibroblast are expression of α-smooth muscle actin 
(αSMA) and the fibronectin (FN) splice variant ectodomain (ED)-A FN (Hinz, 
2010). As its nomenclature suggests, the myofibroblast is defined by contractile 
function rather than αSMA expression per se. It has been shown that “proto- 
myofibroblasts”, which contain stress fibres, but not αSMA, emerge after six days 
of wound healing, with αSMA expressing fibroblasts appearing at around nine 






1.4.1 Myofibroblast Origin 
 
The exact origin of myofibroblasts in fibroproliferative disease has not been fully 
clarified. In the skin, it is recognised that connective tissue fibroblasts acquire 
contractile stress fibres and then express α-SMA (Hinz, 2009). In liver fibrosis, 
hepatic stellate cells and portal fibroblasts are transformed into myofibroblasts, 
while in the kidney epithelial cells undergo epithelial to mesenchymal transition 
to become myofibroblasts (Guyot et al., 2006; Zeisberg & Kalluri, 2008). Epithelial 
to mesenchymal transition has also been demonstrated in lung, kidney and liver 
fibrosis, while pericytes have been shown to transform to myofibroblasts in 
scleroderma scarring (Kim et al., 2006; Rajkumar et al., 2006; Zeisberg & Kalluri, 
2008). 
 
1.4.2 Fibroblast-Myofibroblast Differentiation and 
Tissue Stiffness 
 
The myofibroblast receives constant feedback from the ECM, which regulates its 
role in the wound healing process. In vitro, fibroblast stress fibre formation and 
myofibroblast differentiation will only occur if cells are cultured on substrates 
providing sufficient mechanical tension (Hinz, 2009). 
 
Attempts have been made to quantify the mechanical load required to stimulate 
myofibroblast differentiation and therefore to define what constitutes a “stiff” 
ECM. The provisional matrix of early wounds (<5 days) is estimated to be ~10- 
100Pa, which is comparable with newly polymerized collagen gels often used in in 






show no stress fibre development or αSMA expression (Tamariz & Grinnell, 2002). 
Stress fibres without αSMA expression is first seen in fibroblasts grown in 
conditions of tissue stiffness of ~3000-6000Pa (Discher et al., 2005). 20 000Pa is 
required for the expression of αSMA and it has been shown that the amount of 
αSMA expression increases with increasing tension (Discher et al., 2005). 
 
Figure 1.5 Fibroblast to myofibroblast differentiation as a function of tissue 
stiffness (Discher et al., 2005) 
 
The relationship between mechanical tension and fibroblast phenotype is 
particularly compelling in relation to hypertrophic scarring. It has been known 
since the advent of modern surgery that a wound under tension is particularly 
prone to hypertrophic scarring (Gurtner et al., 2008). In fact, Gurtner and 
colleagues showed that applying mechanical force across a mouse wound 
(effectively counteracting the natural contraction of panniculus carnosus) leads 
to hypertrophic-like scarring (Aarabi, Bhatt, et al., 2007). Furthermore, scar 
development in this model was prevented by interruption of the Focal Adhesion 
Kinase (FAK) signalling pathway (Wong et al., 2012). This demonstrates the key 






hypertrophic scarring and illustrates the potential for therapeutic intervention 
aimed at uncoupling this relationship. 
 
1.4.3 How Do Fibroblasts Sense Mechanical Stress? 
 
Fibroblasts attach to the ECM substrate via integrins, αβ heterodimers that form 
cell receptors anchoring intracellular stress fibres to the ECM (Hynes, 2002). 
When extracellular mechanical stress is applied to fibroblasts, integrins cluster 
into nascent adhesions and then further into focal complexes (~1μm2). If further 
stress is applied classical focal adhesions develop (2-6μm2) (Bershadsky et al., 
2006). 
 
αSMA positive myofibroblasts display significantly larger supermature focal 
adhesions (8-30μm2) (Dugina et al., 2001). Supermature focal adhesions may be 
reduced to classical focal adhesions when αSMA contraction is inhibited or when 
extracellular substrate tension is reduced (Goffin et al., 2006). 
 
Thus, fibroblasts gain information about mechanical tension through the 
interaction between their stress fibres and the ECM through their adhesion sites. 
This information then leads to responses in cell properties such as migration, 
proliferation, survival, differentiation, ECM organisation and remodelling (Vogel 
& Sheetz, 2006). This can occur through intracellular mechanisms, such as 
molecular switches or signal pathways, or extracellular protein unfolding to 
reveal integrin binding sites (Zhong et al., 1998). Similarly, release and activation 
of TGFβ1 contained in the ECM can be brought about by cellular contraction (Wipff 









It is known that focal adhesions allow contractile activity of myofibroblasts to be 
transmitted to the ECM (Hinz et al., 2012), creating a more strained, stiffer 
environment. These mechanical conditions generated by the myofibroblast also 
lead to their sustained fibroproliferative activity (Hinz et al., 2001). Indeed, scar 
development in a murine model of hypertrophic scarring was prevented by 





1.4.4 The Myofibroblast and Fibroproliferative Disease 
 
The production of ECM and generation of contractile force by myofibroblasts are 
integral to normal wound healing. Dysregulation of these processes is the 
hallmark of fibroproliferative disease, whereby normal tissue is replaced with 
fibrotic scar tissue. In the skin this manifests as hypertrophic scars (Atiyeh, 
Costagliola, et al., 2005) scleroderma (Varga & Abraham, 2007) and Dupuytren’s 
disease (Tomasek et al., 1999). Similar scar production underlies 
fibroproliferative disease of the organs, such as the liver, lung and kidney (Hinz, 
2010). 
 
The initiation of fibrosis marks the beginning of a vicious cycle, whereby the ECM 
is stiffened by myofibroblast activity, which then stimulates further myofibroblast 
differentiation and activity. A key research question is whether tissue stiffness or 
myofibroblast differentiation is the initial step in this process. Recent evidence 






preceding the presence of activated fibroblasts or collagen accumulation(Georges 










1.5 The Cytoskeleton 
 
The cytoskeleton is vital for the maintenance of cellular architecture and is 
instrumental to how cells move through, sense and respond to the extracellular 
environment (Lambrechts et al., 2004). The cytoskeleton is comprised of 
microtubules, intermediate filaments, microfilaments and stress fibres (in order 
of decreasing size) (Oshima, 2007). 
 
Microtubules are approximately 25nm in diameter and are concentrated in 
locomotive structures such as cilia and flagella. They are comprised of 
α and β tubulin dimers, which serve to bring about cell motility and division by 
GTPase dependent polymerization (Valiron et al., 2001). Microtubules are also 
important for vesicle transport through the cell (Holzbaur, 2004). 
 
Intermediate filaments are approximately 10nm in diameter and consist of a 
central α-helical domain flanked by variable N and C terminals (Goldman et al., 
2008). This structure allows interaction with a range of proteins at the cell surface 
such as desmosomes, hemidesmosomes, focal adhesions and the extracellular 
matrix (Capetanaki et al., 2007). 
 
 
Considerable attention has been focused on actin microfilaments, the smallest of 
the three cytoskeletal proteins. They are thought to be important for cell motility, 






individual non-polymerized globular actin subunits (G-actin) which assemble into 
filamentous fibres (F-actin) (Lambrechts et al., 2004). 
 
After injury, changes in the composition, organization and tension of the ECM , as 
well as the action of growth factors, stimulate fibroblast development of stress 
fibres (Werner & Grose, 2003). These stress fibres are initially composed of 
cytoplasmic actins (Tomasek et al., 2002). With increasing ECM tension, α-smooth 
muscle actin (αSMA) is expressed (see above), which marks the phenotypic 
transition from fibroblast to myofibroblast (Hinz & Gabbiani, 2010; Tomasek et 
al., 2002). Stress fibres in mammalian cells are classified according to their 
relationship to focal adhesions: ventral adhesions attach to focal adhesions at both 
ends, dorsal stress fibers attach to focal adhesions at one end and transverse arcs 
do not attach to focal adhesions directly (Naumanen et al., 2008). Stress fibers are 
thought to be important for maintaining a balance between contraction and 




1.5.1 Actin dynamics during wound healing 
 
 
Actin dynamics are integral to the wound healing process. After wounding, cells 
respond to a variety of stimuli to remodel their actin cytoskeleton, which brings 
about changes in cell contraction, adhesion, motility or phenotype. In the case of 
keratinocytes at the wound edge, this leads to migration across the wound matrix 






fibres and take on a myofibroblast phenotype (Cowin et al., 2003; Jacinto & 
Wolpert, 2001; Lambrechts et al., 2004). 
 
Consequently, understanding the regulation of actin dynamics and the role they 
play in different types of wound healing is of considerable interest. For example, 
previous work by Cowin has demonstrated differential expression of F-actin in 
scar less fetal wound healing (F-actin predominately expressed in the epidermis) 
versus scar forming adult wound healing (F-actin predominately expressed in the 
dermis (Cowin et al., 2007; Cowin et al., 2003). 
 
1.5.2 Actin cytoskeleton, cell motility and cell matrix 
adhesion 
 
The actin cytoskeleton, cell motility and cell matrix adhesion are all intimately 
connected. In order to migrate through the ECM cells form lamellipodia and 
filopodia at their leading edge, which then form adhesions with the matrix, 
allowing movement of the cell body (Partridge & Marcantonio, 2006). 
 
Lamellipodia are a cell projection consisting of a network of branched actin 
filaments, whose assembly is regulated by the Rho GTPase family. Surface 
receptors are linked to the actin cytoskeleton allowing force to be produced for 






Filopodia are long parallel actin filaments arranged into bundles that cause 
elongation of the cell. This elongation is regulated primarily by Cdc42GTPase and 
the Ena/VASP family of proteins and formins (Hotulainen & Lappalainen, 2006). 
Membrane ruffles are brought about by the dynamic movement of the cell 
membrane due to lamellipodia and filopodia formation. Lamella are formed away 
from the leading edge of the cell by the interaction between stress fibers and the 
proteins tropomyosin and myosin II (Le Clainche & Carlier, 2008). 
 
The interaction between the actin cytoskeleton and the ECM occurs through 
highly dynamic, temporary adhesions known as focal complexes. These adhesions 
are formed by actin polymerization underneath lamellipodia. These have been 
described as a “molecular clutch” which connects the cytoskeleton to the matrix, 
thereby allowing actin-myosin generated tension to bring about cell traction (Le 
Clainche & Carlier, 2008). Focal complex function is a complex process determined 
by interaction between integrin-ECM, integrin-actin binding proteins and actin 
filament-actin binding protein interactions. In this way focal complexes link the 
ECM to the actin cytoskeleton, essentially functioning as mechanosensors which 
can then influence maturation of adhesion sites and recruitment of signaling or 
structural molecules (Lambrechts et al., 2004; Le Clainche & Carlier, 2008). Under 
certain conditions focal complexes become larger, more stable adhesions known 
as focal adhesions, which are associated with stress fiber development and 
fibroblast transformation to myofibroblasts (Hinz, 2010). 
 
A number of proteins have been identified as essential mediators of the 






proteins, including vinculin, talin, paxillin, α-actinin and Src kinase are involved in 
signaling pathways initiated by cell matrix adhesion. Vinculin has been shown to 
stabilize adhesions during maturation of focal complexes into focal adhesion, 
while talin helps to link integrin receptors to both the actin cytoskeleton and ECM 
ligands (Le Clainche & Carlier, 2008). Paxillin allows recruitment of a variety of 
different proteins to focal adhesions as well as acting as a signal transducer to 
produce changes in cytoskeletal structure and gene expression (Cowin et al., 
2003). 
 
Improved understanding of the specifics of the complex signaling pathways 
associated with adhesion sites, as well as the role of adaptor proteins like those 
described will help understanding of cell motility and adhesion during normal and 
pathological wound healing. 
 
1.6 Flightless Protein 
 
1.6.1 The gelsolin family of actin remodeling proteins 
 
 
Actin filaments are regulated by actin remodeling proteins, which can sequester, 
cross link and nucleate actin filaments. More than 100 such proteins have been 
identified, including ADF/cofilin family, profilin family, gelsolin superfamily, 
thymosins, capping proteins and the Arp2/3 complex (Dos Remedios, Liew, et al., 
2003)(Dos Remedios, Liew, et al., 2003). Of these, the gelsolin superfamily, which 






(Flii) has been shown to be integral to reorganization of the actin cytoskeleton. 
They function by severing pre-existing actin filaments, capping the fast-growing 
filament ends, while nucleating or bundling actin filaments into new cytoskeletal 
structures (Archer et al., 2005; Goshima et al., 1999; Y. T. Liu & Yin, 1998). 
 
The gelsolin superfamily is characterized by 3 to 6 homologous gelsolin like 
structural domains (G1-G6 segmental domains), 3 actin binding regions and 
various calcium independent monomer and filament domains. Despite 
considerable homology across the gelsolin family, differences suggest that 
individual proteins have gained novel functions in addition to actin remodeling 
(Archer et al., 2005; Campbell et al., 1997). For example, villin contains an 
additional actin binding domain (“villin head piece”); supervillin contains an N- 
terminus domain capable of protein-protein interactions nuclear localization; and 
Flii contains an N-terminus Leucine Rich Repeat (LRR) domain capable of protein- 









Figure 1.6 Comparison of Flii and gelsolin proteins Flii is a member of the 
gelsolin family and possesses two gelsolin like domains, as well as a unique 
Leucine Rich Repeat domain (LRR) on its N-terminus (Witke et al., 1995) 
 
 
The gelsolin superfamily is essential to a variety of processes important in wound 
healing, such as cell motility, apoptosis and gene expression (Silacci et al., 2004). 
Studies indicate that members of the gelsolin family are involved in the regulation 
of wound repair and as such, may be targets for therapies to help improve wound 
healing and reduce scar formation (Cowin et al., 2007). For example, increasing 
cellular levels of gelsolin has been shown to enhance wound closure, while 
decreasing gelsolin leads to delayed wound healing (Cunningham et al., 1991; 
Witke et al., 1995). For these reasons, Flii was identified as a protein of interest in 
wound healing research upon its discovery in the 1990s (Campbell et al., 1997). 
Since that time it has been identified as a negative regulator of wound healing 
and a promising candidate as a target for novel wound healing therapies (Adams 






1.6.2 Flightless I (Flii) Protein 
 
 
Flii was discovered as a gene mutation in Drosophila melanogaster, located in the 
subdivision 19F on the X chromosome. Flii is the most conserved protein in the 
gelsolin family but is unique in containing a LRR domain at its N-terminus 
(Claudianos & Campbell, 1995). It was named due to the irregular actin 
organisation observed in Flii heterozygote Drosophila that resulted in defective 
flight muscles (Campbell et al., 1993). In more severe mutations, Drosophila 
embryos suffer incomplete cellularisation with irregularities in gastrulation and 
mesoderm invagination during early embryogenesis leading to a disorganised 
cytoskeleton. Homozygous expression is embryonically lethal, failing to develop 
beyond the blastocyst stage. A trophoblast cell layer is formed, but the 
development of the egg cylinder fails, resulting in complete embryonic 
degeneration (Campbell et al., 2002) (Figure 1.7). The insertion of a cosmid clone 
containing Flii to homozygous Flii embryos restores normal development 
(Campbell et al., 2002). 
 
The human homologue of the Flii gene was subsequently discovered in 1997 
(Campbell et al., 1997). The human Flii locus has been mapped to human 
chromosome 17p11.2. The deletion of this region results in the congenital 
syndrome Smith-Magenis (SMS) syndrome, which comprises behavioural and 
developmental abnormalities (Elsea & Girirajan, 2008; Y. T. Liu & Yin, 1998). Most 






Retinoic Acid Induced 1 (RAI1), but Flii may contribute to this disease although 
this is yet to be demonstrated (Girirajan et al., 2006). 
 
Flii’s essential role in embryogenesis has also been shown in mammals as well as 
Drosophila. Normal development is restored to a homozygous Flii mouse by a 
human transgene containing the complete human Flii gene (Campbell et al., 2002). 
The human Flii transgene was used to develop a Flii transgenic mouse (FliiTg/Tg), 
while a heterozygous Flii mouse (Flii+/-), with half the normal amount of Flii 
protein, was also developed. Both genotypes appear phenotypically normal and 






1.7 Gastrulation and cellularisation defects in Flii homozygous embryos. 
WT embryo showing normal mesoderm invagination with cytoplasmic 
incorporation and gastrulation. B-C Unincorporated cytoplasm (arrows) seen in 
Flii homozygous embryos. D Incomplete and irregular invagination occurs in Flii 
homozygous embryos. E-F Ventral nuclei move towards the centre of the cell in 
slightly older Flii homozygous embryos and pole cells (pc) reformed. Scale bar = 













Flii is a 1256 amino acid protein with a molecular weight of 143kDa (Davy et al., 
2000). It possess duplicated domains containing three repeated 125-150 amino 
acid sequences corresponding to the six gelsolin-like (g1-6) segmental repeats 
which identify it as a member of the gelsolin family of proteins (Claudianos & 
Campbell, 1995). Flii is unique amongst the gelsolin family in containing a leucine 
rich repeat (LRR) domain at the N-terminal end of its mRNA sequence. Other 
proteins containing this domain utilise it for protein-protein or protein-lipid 
interactions, which may underlie the diversity of functions Flii is thought to 
possess (Kobe & Kajava, 2001). Flii is the only known protein in which gelsolin- 
like and LRR domains exist together (Kopecki & Cowin, 2008). 
 
The unique structure of Flii has led to a number of possible mechanisms for its 
regulatory role in wound healing. As an actin remodeling protein, Flii is important 
in the regulation of the actin cytoskeleton and consequently, the motility, 
contraction and adhesion of cells (Davy et al., 2000). Davy demonstrated that Flii 
is localized to various cell migratory structures, such as filopodia, neuritis and 
growth cones, while co-localizing with other cytoskeletal structures related to 
motility (Davy et al., 2000). 
 
A recent study has shown that Flii acts by inhibiting actin polymerization, while 






the growth of actin and contributes to actin filament stability. When Flii is reduced 
filament ends are not capped leading to increased actin and focal adhesion 
turnover as well enhanced cell motility (Mohammad et al., 2012). There is also 
evidence to suggest that Flii may actually be secreted by fibroblasts and so may 
act in a similar manner to the secretory phenotype of gelsolin that scavenges 
extracellular actin following tissue injury (Cowin et al., 2012). 
 
Flii co-localizes with several molecules involved in cytoskeletal re-organisation, 
such as Ras, Cdc42 and RhoA. It associates with Ras via its LRR domain. Ras 
proteins regulate the actin cytoskeleton by associating with Raf-1 activating 
mitogen-associated protein kinase (MAPK) and this represents a possible 
pathway by which Flii regulates cell response during wound healing (Campbell et 
al., 1997; Davy et al., 2000; Goshima et al., 1999). 
 
More recent work has shown that Flii modulates focal adhesions and filamentous 
actin stress fibres in a Rac-1 dependent manner (Kopecki, O'Neill, et al., 2011). Flii 
co-precipitates with focal adhesion proteins talin, paxillin and vinculin (Kopecki 
et al., 2009). In vivo, elevated Flii leads to increased stress fiber formation by 
impaired focal adhesion turnover and enhanced formation of fibrillar adhesions. 
Conversely, Flii knockdown increases the percentage of focal complex positive 
cells (Kopecki, O'Neill, et al., 2011). Flii knockdown cells exhibit lower levels of 
activated β1-integrin and vinculin, without any change in talin levels. This 
suggests that Flii may promote the recruitment of focal adhesion proteins like 
vinculin, which through its interaction affects β1-integrin activation (Mohammad 






Flii’s multifactorial potential is emphasized by its distribution throughout the cell. 
Although primarily nuclear Flii is also capable of nuclear to cytoplasmic 
translocation, a property it shares with several other members of the gelsolin 
superfamily (supervillin, gelsolin and CapG) (Davy et al., 2001; Lei et al., 2012). 
Flii is secreted from macrophages and fibroblasts in response to wounding and 
LPS stimulation respectively (Lei et al., 2012). Flii has been shown to localize to 
late endosomes/lysosomes but not to pathways associated with classical 
secretory mechanisms, such as the trans-Golgi network, recycling endosome- 
associated SNARE protein Vti1b or VAMP3 (Lei et al., 2012). 
 
Like gelsolin, Flii also has the ability to regulate gene transcription probably 
through the pools of Flii found localized to cell nuclei (Archer et al., 2005). Flii 
binds to oestrogen and thyroid hormone receptors, as well as co-activators GRIP1 
and CARM1 (Y. H. Lee et al., 2004). Flii also inhibits β-catenin and LEF1/TCF- 
mediated transcription (Lee & Stallcup, 2006). Flii has been identified as a 
substrate for cytokine-independent survival kinase (CISK) acting downstream of 
PI-3kinase/CISK signaling pathway. CISK phosphorylates Flii, modulating its 
activity as an oestrogen co-receptor and potentially impacting on actin 
reorganization and endosome trafficking (Xu et al., 2009). 
 
Flii also interacts with proteins known as enhancers of nuclear receptor-directed 
transcription, such as GRIPI (p160), SRC-1, pCIP and TRAM1 (Claudianos & 
Campbell, 1995). These proteins bind to histone acetyltransferase CBP(p300) and 
arginine methyltransferase CARM1 and promote histone modifying activity in the 






protein also bind nuclear actin like proteins such as BAF53 and Arp4, which form 
integral components of the co-activator complex (Y. H. Lee et al., 2004). 
 
As mentioned, Flii is unique among the gelsolin family of proteins in possessing a 
LRR domain. This allows protein-protein/protein-lipid interactions which 
mediate receptor-ligand affinity (Kobe & Kajava, 2001). Two proteins that bind to 
Flii’s LRR domain have been identified and are known as Flii leucine rich repeat 
associated protein (FLAP)1 and FLAP2 (Y. T. Liu & Yin, 1998) (Figure 1.8). It is 
postulated that interaction between Flii and FLAP1 may be important in 
regulating the β-catenin dependent Wnt signaling pathway (Lee & Stallcup, 2006). 
Flii antagonizes synergy between FLAP1, p300 and β-catenin by acting 
synergistically in a GRIP1 co-activator complex with nuclear receptors, and 




Figure 1.8 Schematic diagram of Flii illustrating its role as a nuclear 
receptor co-activator and formation of the co-activator complexes at the 
promoter of an NR responsive gene. NR denotes nuclear hormone receptor 






Flii has also been shown in vitro to inhibit activated calcium/calmodulin 
dependent protein kinase type II (CaMK-II) resulting in suppression of β-catenin 
activity (Seward et al., 2008). 
 
A number of recent studies have provided compelling evidence that Flii has an 
important role as an immune-modulator (Dai et al., 2009; Hayashi et al., 2010; Lei 
et al., 2012; Li et al., 2008). Flii’s N-terminus LRR domains share nearly 50% 
homology to the LRR domains of toll-like receptor (TLR). TLRs function as 
detectors of injury or infection by binding to pathogen-associated molecular 
pattern molecules (PAMPs) (e.g. LPS from gram negative bacterial cell walls) or 
damage-associated molecular pattern molecules (DAMPs) (e.g. ECM cleavage 
products or molecules such as HMGB1 (High Mobility Group Ptorein B1) 
released from damaged cells) (Bianchi, 2007). After binding TLR signaling 
pathways are activated leading to the secretion of pro-inflammatory cytokines. In 
vitro, Flii binds to the TLR adaptor protein MyD88 through its interaction with 
nucleoredoxin which inhibits MyD88 binding to TLR4 and reduces inflammatory 
cytokine secretion (Hayashi et al., 2010; T. Wang et al., 2006). Flii has also been 
localized to late endosome/lysosomes in fibroblasts and macrophages where it 
may also dampen inflammation (Lei et al., 2012; Li et al., 2008). 
 
The TGF-β family has been one of the most investigated cytokines in relation to 
wound healing, with particular focus on developing novel therapies that may 
modulate TGF-β1/ TGF-β3 ratio and improve wound healing (Shah et al., 1994, 
1995). Flii has been shown to interact with all TGF-β1 isoforms in vitro and 






well as nuclear Akt, suggesting Flii may regulate TGFβ activity. This is in keeping 
with in vivo data where Flii+/- wounds display decreased TGF-β1/ TGF-β3 ratios 
and FliiTg/Tg wounds display increased TGF-β1/ TGF-β3 compared to controls 
(Campbell et al., 1993). 
 




Work over the past decade has shown that Flii is a negative regulator of wound 
healing (Cowin et al., 2007). Flii affects the proliferation and cell motility of 
keratinocytes, while also affecting dermal fibroblast motility, proliferation and 
collagen production (Cowin et al., 2007). In vivo, Flii+/- mice show improved 
wound healing, with increased epithelial migration and smaller more contracted 
wounds, while FliiTg/Tg mice display increased wound area and dermal gap, 
delayed epithelial migration and reduced cell proliferation (Cowin et al., 2007; 
JJackson et al., 2012; Kopecki & Cowin, 2008; Kopecki et al., 2013) (Figure 1.9). 
 
Flii has also been investigated in several other in vivo models of wound healing. 
Using a model of partial thickness burn wounds, Flii+/- mice displayed improved 
wound healing, with decreased levels of pro-scarring cytokine TGF-β1 and 
increased levels of anti-scarring TGF-β3 compared to control. On the other hand 
FliiTg/Tg mice displayed the opposite, with impaired wound healing and increased 
levels of TGF-β1/decreased TGF-β3. Similarly reducing Flii has been shown to 
improve wound healing in a diabetic mouse model of wound healing. This is 






(Ruzehaji, Kopecki, et al., 2013; Ruzehaji, Mills, et al., 2013). Flii has also been 
investigated as the target for a novel treatment of Epidermolysis Bullosa (EB). In 
two models of EB, FliiTg/Tg displayed more severe blistering compared with 
control, while reducing Flii in Flii+/- mice less blister severity (Kopecki, Arkell, et 
al., 2011). A Flii neutralizing antibody has been developed and has been shown 
to improve healing in acute and chronic wounds in murine and porcine models 
(Kopecki, Ruzehaji, et al., 2013). 
 
Recent evidence has emerged of a possible role for Flii in tissue regeneration 
(Strudwick et al., 2017). In a murine whisker follicle regeneration model Flii+/- 
showed repaired or delayed regenerative potential (Waters et al., 2011). In a 
murine distal amputation model, a regenerative phenotype was observed in 
FliiTg/Tg mice in both distal and proximal amputations, whereas regeneration 
occurred only in distal models in WT mice (Strudwick et al., 2017) 
 
Flii has also recently been investigated in relation to psoriasis (Chong et al., 2017). 
Psoriasis is an inflammatory autoimmune skin condition, in which a Th1 and Th17 
drive abnormal keratinocyte differentiation, proliferation and expression of Toll 
Like Receptors 1, 2, 4, 5 and 9 (Chong et al., 2017). As mentioned, Flii has 50% 
homology to TLRs and is known to be involved in the TLR4 pathway (Ruzehaji et 
al., 2013). Elevated levels of Flii were seen in human psoriatic plaques and in a 
model of murine psoriasis Flii+/- mice demonstrated reduced inflammation, 
erythema and skin thickening. Analysis of plaques showed reduced inflammatory 
cell numbers, reduced keratinocyte proliferation and reduced TLR-4 expression 






Flii inhibits cell adhesion and is an important regulator of actin remodeling, cell 
signaling and has been shown to function as a nuclear receptor co-activator 
(Kopecki & Cowin, 2008; Kopecki et al., 2013). These properties are vital to the 
ability of tumour cells to spread and invade surrounding tissue. Flii levels have 
been shown to be significantly elevated in human squamous cell carcinoma (SCC) 
and FliiTg/Tg mice demonstrated increased incidence and severity of SCC 
comparted to WT controls (Kopecki et al., 2015). SCC analysis in FliiTg/Tg mice also 
revealed significantly lower levels of caspase 1 and annexin-V, suggesting 
decreased apoptosis of tumour cells and may contribute to tumour progression 
(Kopecki et al., 2015). Exogenous reduction of Flii levels also reduced tumour size 














Figure 1.9. Representative partial thickness burn wounds seen in Flii mice. 
A Partial thickness burn wounds seen at 3, 7 and 14 days post injury in Flii+/-, WT 
and FliiTg/Tg mice. Dotted lines refer to wound margins. The ruler represents mm. 
B shows higher magnification of day 14 wounds, i, ii and iii show Flii+/-, WT and 
FliiTg/Tg mice respectively. Scale bar = 2mm. Adapted with permission from 






1.7 Hypertrophic Scarring 
 
1.7.1 Defining hypertrophic scarring 
 
Hypertrophic scarring is a fibroproliferative disease of the skin, in which an 
aberration of normal wound healing pathways result in the production of 
excessive collagenous extracellular matrix. Clinically this manifests as a raised, 
red, tender, pruritic scar, which is prone to contracture over time (Figure 1.10). 
These scars may cover large areas, but do not, in contrast to keloids, extend 
beyond the original margins of injury. In the majority of cases the scarring 
enlarges over a period of months, then gradually regresses over a few years 
(Rudolph, 1987). 
 
Histologically, hypertrophic scars are characterized by dermal thickening due to 
collagen deposition, parallel collagen fibre orientation, loss of dermal appendages, 
absence of elastin and flattening of the epidermis (Santucci et al., 2001). A key 
distinguishing feature is the presence of whorls of immature collagen that consist 
of collagen fibrils, increased type 3 collagen, small blood vessels and acidic 













Figure 1.10 Complications of hypertrophic scarring Typical appearance of a 
hypertrophic scar (A) as well as an example of the deformity caused by scar 
contracture across the wrist joint (B and C) (Aarabi, Bhatt, et al., 2007) 











While most commonly associated with burn injury, hypertrophic scarring may 
occur after any skin injury, particularly those involving the full thickness of the 
dermis. Prevalence after deep dermal burn injury is estimated at 75%, and this 
figure is higher in children,  and dark skinned individuals (Bombaro et al., 2003). 
 
Hypertrophic scarring imparts a devastating burden of disease, including 
disfigurement, pain and disability. Consequently, it is associated with significant 
social and psychological comorbidities such as low self-esteem, social isolation, 
prejudicial societal reaction, depression and suicide (Engrav et al., 2007). 
Rehabilitation for hypertrophic scarring is laborious and costly, requiring 
thousands of hours of physical therapy and often, multiple surgical procedures. In 
the US alone, this treatment is estimated to cost in excess of $4 billion every year 
(Chen et al., 2017). 
 
The antecedents to hypertrophic scarring, such as deep burn injury, wound 
tension, wound infection or the presence of foreign material, were identified at the 
beginning of modern surgery. However, how these lead to changes at the cellular 










Given its strong association with burn injury, an understanding of hypertrophic 
scarring is not possible without some discussion of burn injury management. 
 
1.7.3.1 Burn Injury 
 
 
The  pathophysiology of the burn wound is a function of both temperature and 
exposure time i.e. a high temperature for a short time may cause the same tissue 
damage as a lower temperature for a longer time (Andrew et al 2017). Jackson 
described three zones of histopathological injury: coagulation, stasis and 
hyperaemia (Jackson, 1953). The zone of coagulation is comprised of eschar or 
necrotic tissue and is closest to the heat source. This is surrounded by the zone of 
stasis, where there is only moderate tissue damage, but slow blood flow and 
oedema due to capillary leakage and cell membrane disruption (Baskaran et al., 
2001; Despa et al., 2005). Poor blood flow in this zone may lead to local tissue 
ischaemia and further necrosis (Zawacki, 1974). Surrounding the zone of stasis is 
the zone of hyperaemia, in which cell damage is minimal and blood flow gradually 
increases resulting in early spontaneous recovery. Burn depth may increase over 
48-72 hours, as the zone of stasis becomes necrotic. 
 
Burn depth is vital to their outcome and they are classified accordingly. Superficial 






completely within 3-5 days. Partial thickness burns involve the entire epidermis 
and portions of the dermis. They are divided into superficial partial and deep 
partial thickness. Superficial partial burns extend to the superficial dermis and are 
pink, moist and painful to touch. Blistering is common as a result of serum 
accumulating between the superficial dermis which has detached from the deep 
dermis (Andrew et al 2017). They will usually heal in two weeks without a scar 
via regenerative elements within sweat glands and hair follicles. Deep partial 
thickness burns involve the entirety of the epidermis and extend to the reticular 
layer of the dermis. They are a mottled white-pink colour and have variable 
sensation due to destruction of superficial cutaneous nerves. These wounds may 
heal within 3 weeks but are at increased risk of developing hypertrophic 
scarring. Full thickness burns involve the entire epidermis and dermis. They are 
brown-black, leathery and insensate. Healing will be extremely slow and 
associated with marked contraction and hypertrophic scarring. 
 
 
1.7.3.2 History of burn injury management 
 
 
Since 1500BC various emollients have been used to cover the burn wound, often 
with abysmal results. The Ebers Papyrus (1534BC) describes a five day regimen 
of treatments with various combinations of mud, cow dung, bees’ wax, ram’s horn 
and barley porridge (Ravage, 2004). Hippocrates proposed the application of 
melted pig skin mixed with bitumen (Pack, 1930) while during the Renaissance, 







By the early 20th century burn treatment comprised of tannic acid spray, as well 
escharotic and bacteriolytic agents such as gentian violet and the flavine 
compounds (Heslop, 1998). The first major advance in burn wound management 
came during World War II, where the introduction of aerial warfare led to 
previously unseen numbers of large burns. The work of pioneering plastic 
surgeons Harold Gillies and Archibald McIndoe led the discontinuation of tannic 
acid sprays and the introduction of pressure absorptive dressings (Heslop, 1998). 
The greatest legacy of this period was the treatment of burns in specialist 
multidisciplinary centres, such as McIndoe’s East Grinstead Hospital. McIndoe is 
recognized as the first surgeon to identify the importance of ongoing physical and 
psychological rehabilitation for burn patients, which led to the establishment of 
the famous “Guinea Pig Club” (McCleave, 1961). 
 
Overwhelming infection and sepsis was still a problem that led to high mortality 
rates following large burns, even despite the introduction of penicillin (Heslop, 
1998). During the 1950s the establishment of the Shriners’ burn institutes in the 
US led to substantial advances in the supportive treatments for burn patients 
such as aggressive fluid resuscitation and the use of topical antibiotics such as 
silver (Heslop, 1998). 
 
One of the most significant advancements in burn surgery came in the 1960s from 
the unlikely location of Slovenia, behind the “Iron Curtain”. Zora Janžekovič 
introduced the concept of early excision of devitalized tissue to prevent it 
becoming a source of inflammation and a nidus of infection (Janzekovic, 1970). 






despite initial scepticism from the West, has become standard care for burns 
patients (Janzekovic, 2008). 
 
Further progress in reducing post-burn hypertrophic scarring has been slow. 
Promising new surgical technologies, such as cultured keratinocytes and dermal 
allografts have had only limited success in preventing or reducing hypertrophic 
scarring (Atiyeh, Hayek, et al., 2005; Janzekovic, 1970). Non-surgical treatments, 
such as massage, silicone dressing and pressure garments are anecdotally 
effective in reducing scar severity and contracture development, but they lack a 
strong evidence base for their efficacy or mechanisms of action. Other techniques 
such as steroid injection or radiotherapy are limited to small areas of scarring and 
carry a high risk of recurrence (Franz et al., 2000; Mustoe et al., 2002; Rahban & 
Garner, 2003). Thus, despite the ability to save the lives of patients with severe 
burn injuries, preventing and treating the sequelae of these injuries, namely 
hypertrophic scarring, remains limited. 
 
1.7.3.3 Current management of hypertrophic scarring. 
 
Minimising risk factors for hypertrophic scarring 
 
Risk factors predisposing to hypertrophic scarring have been identified since the 
beginnings of modern surgery. These include factors such as deep burn injury, 
wound tension, wound infection or the presence of foreign material (Aarabi et al., 
2007). Modifying these risk factors can prevent or reduce hypertrophic scarring. 
Thus, wounds should undergo appropriate debridement or excision. Closure of 






Vigilance should be exercised in populations predisposed to hypertrophic 
scarring, such as children or individuals with dark skin, to ensure early detection 
and treatment. Burns deeper than mid or deep dermal level are at particular risk 
of hypertophic scarring, particularly those that take longer than three weeks to 
heal (Deitch et al., 1983). These patients should undergo early tangential 
excision and split thickness skin grafting in order to reduce the risk of 
hypertrophic scarring (Finnerty et al., 2016) 
 
Management of the developing or established hypertrophic scar 
 
1. Non-invasive management 
 
 Avoidance of UV exposure 
 
Excessive exposure to UV light has been show to lead to hyperpigmentation 
of the scar, even after the resolution of hypertrophic scarring (Haedersdal 
et al., 1998). 
 
 Application of moisturizer 
 
Application of moisturizer to immature scars has been associated with 
reduction in hypertrophic scarring. The moisture content of keratinocytes 
has been shown to influence keratinocyte behavior in vitro, while increased 
trans-epidermal water loss (TEWL) is associated with increased scarring 
(O'Shaughnessy et al., 2009). 
 
 Scar Massage 
 
Scar massage is widely accepted to reduce development of hypertrophic 
scarring. The mechanism for this remains unclear, with possible theories 





massage also assists with lymphatic drainage and stretching of 




Taping of surgical incisions with Steri-Strips™ or Hypafix® has been shown 
to reduce the probability of hypertrophic scarring, especially for incisions 
perpendicular to relaxed skin tension lines. This is likely due to reducing 






 Silicone dressings 
 
Silicone dressings have been widely used to reduce the incidence of 
hypertrophic scarring since the first evidence of their efficacy was 
presented in the early 1980s. Their effect is thought to be related to 
preventing TEWL. Dehydration of the stratum corneum is associated with 
an increased inflammatory response and increased scarring (Mustoe, 
2008). A Cochrane review showed only weak evidence for the efficacy of 




Physiotherapy is an integral component of burn rehabilitation particularly 
in preventing and managing contractures through splinting and range of 
motion (ROM) exercises. Splinting is particularly important for burns to 
body areas prone to contracture such as the neck, elbow, axilla and hands 
(Jordan et al., 2000). 
 
 
 Pressure garments 
 
Pressure garments are used both prophylactically and to treat established 
hypertrophic scars. Their mechanism of action is poorly understood. 






collagen turnover and decreasing oedema; decreased myofibroblast 
activity due to reduction of oxygen tension; action via cell 
mechanoreceptors or stimulation of neurogenic inflammation. Pressure 
garments are also useful in alleviating oedema, pruritus and pain (Anzarut 
et al., 2009). 
 





Corticosteroids have been shown to inhibit extracellular matrix production 
and excessive collagen deposition, as well as reducing pro-inflammatory 
cytokine production and inhibiting angiogenesis (Cohen & Diegelmann, 
1977). They are only effective as an intra-lesional treatment i.e. topical 
application has not been shown to be effective. Their use is limited to small 
areas due to the pain of multiple injections and the systemic side effects of 
corticosteroids, particularly immunosuppression. Hence, they are rarely 




Imiquimod is an immunomodulator that acts on macrophages, monocytes 
and dendritic cells to reduce scarring. Evidence is limited regarding its 
efficacy and most evidence comes from studies involving keloids (Berman 








Bleomycin sulfate, a secondary metabolite of a strain of Streptomyces has 
anti-tumour, anti-viral and anti-bacterial activity. It was proposed by 
Bodokh and Brun in 1996 as an alternative therapy for keloids and 
hypertrophic scarring (Bodokh & Brun, 1996). Bleomycin has been found 
to cause necrosis of keratinocytes, induce inflammatory infiltration and 
expression of various adhesion molecules in normal skin (Rabello et al., 
2014). Despite these findings the exact mechanism by which bleomycin 
exerts its effect on scarring is unclear (Rabello et al., 2014). Evidence for 
efficacy is limited to small areas of scarring due to the pain of multiple 
injections and systemic side-effects (Aggarwal et al., 2008). 
 
 
 5-Fluorouracil (5-FU) 
 
5-FU has been used for over three decades to prevent scar formation after 
glaucoma surgery and is thought to act via inhibition of fibroblast 
proliferation. It is often combined with surgical excision and triamcinolone 
acetonide to avoid excessive inflammation. Evidence for its efficacy mainly 




Verapamil is a Ca2+ channel antagonist known to decrease collagen 
synthesis and stimulate pro-collagenase. It is delivered via intra-lesional 
or perilesional injection. Efficacy has been shown in keloids, Dupuytren’s 








Laser therapy has been shown to be useful in treating various aspects of 
hypertrophic scarring. (Hantash et al., 2007; Hantash & Mahmood, 2007).  
Treatment effects are though to occur via photothermolysis of scar 
microvasculature, decreased cellular activity from laser induced anoxia or 
from collagenolysis by laser stimulation of cytokine release (Brewin, 
2014). Different wavelengths and treatment regimens are tailored to the 
desired outcome, which include improvement in pliability, texture, 
erythema and pruritus (Brewin, 2014). Both pulsed dye laser, ablative 




Surgery is important both the prevention of hypertrophic scarring as well 
as managing existing hypertrophic scars. It has both functional and 
aesthetic considerations. As described above, surgical management of the 
acute burn begins with assessment of burn depth and tangential excision 
of any burn that extends to the deep dermis or below. Excision of the burn 
removes necrotic and inflamed tissue, which would otherwise act as a 
nidus for infection, retard wound healing and predispose to hypertrophic 
scarring (Ong et al., 2006). Antibacterial wound dressings, such as silver 
and prophylactic antibiotics are administered to minimise the risk of 
infection. 
 
Surgery to counter the disability and deformity caused by scar contracture 
is an all too common occurrence for burn survivors, particularly those with 
burns over the flexor surface of joints. The “reconstructive ladder” is used 





range from simple excision and primary closure, to skin grafting, loco- 
regional flaps (including Z-plasty, W-plasty and V-Y-plasty) through to free 
flap transfer (Cameron et al., 2010). For large areas, tissue expansion may 






tissue transfer. This involves gradual expansion of silicone balloons under 
donor tissue with saline solution over 3-6 months prior to surgery. 
A range of surgical techniques exist which aim to improve the appearance 




Dermabrasion involves controlled mechanical removal of epidermis and a 
portion of the dermis in order to smooth scars with irregular services. Re- 
epithelialisation occurs from remaining dermal appendages. 
Dermabrasion may be used in conjunction with split thickness skin grafting 




Radiotherapy is described almost exclusively for treatment of keloids as an 
adjunct to surgical excision, with recurrence reduced to as low as 10-20% 




It was hoped that the use of autologous cells would mark a major 
breakthrough in burn surgery, which would obviate the problem of limited 
donor skin in large burns. However, the technique was hampered by the 
long delay to culture, the fragility of cultured grafts, unpredictable 
ingrowth and expense. The technique has been partially improved by the 






Non-cultured (ReCell®) cells are now also used. These cells are harvested 
from the dermal-epidermal junction of non-injured skin by a combined 
physical-enzymatic perioperative procedure. Cell population includes 
basal keratinocytes, papillary dermal fibroblasts, melanocytes and 
Langerhan’s cells. Cells are then delivered by spray. Advantages of this 
technique are small donor sites, but a significant disadvantage is the lack 
of any dermal component. Autologous cell grafting can be used in 
conjunction with dermal substitutes and widely meshed skin grafts (Wood 





Lipofilling (autologous fat grafting) is useful in modifying the thickness and 
texture of scar tissue, leading to more supple scars. Furthermore, recent 
findings suggest adipose derived stem cells (ADSCs) release multiple 
growth factors stimulating angiogenesis and extracellular matrix 
deposition (Coleman, 2006). 
 
1.7.4 Current understanding of the pathophysiology of 
hypertrophic scarring 
 
Hypertrophic scarring represents an aberration of the normal wound healing 
process (Aarabi et al. 2007). The basic chronology of hypertrophic scarring is 
understood as follows: a prolonged inflammatory phase results in persistence of 
myofibroblasts in the wound and elevated levels of fibrogenic cytokines, such as 
TGFβ-1 and Connective tissue growth factor (CTGF) (Wynn, 2008). Myofibroblasts 






a disorganised manner (Hinz, 2010). This results in a raised, red, tender scar, 
which is prone to contracture over time (Baker et al. 2009). 
 
Research has therefore focused on particular elements of the wound healing 
process that may play a key role in its regulation, and therefore its dysregulation 
(Gurtner et al. 2008). These include focusing on the inflammatory response to 
injury, elements of the extracellular matrix and specific cells types. The current 






Clinically, increased inflammation due to deep burns or infection is strongly 
associated with hypertrophic scarring. Despite this, anti-inflammatory therapy 
has not been effective in preventing or treating hypertrophic scarring (Kamp, 
2003). This led to the theory that is was not the severity, but the type of 
inflammatory response that is important in hypertrophic scarring. 
 
 
The T-helper-2 cell response (Th2) which involves interleukins-4, 5, 10 and13 is 
strongly linked to fibrogenesis stimulating expression of genes for procollagen-I, 
procollagen-III and tissue inhibitor of metalloproteinase (TIMP) (Doucet et al., 
1998; Wynn, 2004). In keeping with this the T-helper-1 response (Th1) leads to 
expression of pro-apoptotic genes and activation of nitric oxide synthase (NOS), 






The TGF-β superfamily has been extensively investigated in relation to wound 
healing and scar formation. TGF-β has been shown to be integral for the 
ontogenetic shift from scarless foetal healing to adult scar forming wound healing 
(Chen et al., 2005). TGF-β1 and TGF-β2 are pro-fibrotic: they are mitogenic for 
fibroblasts, while stimulating angiogenesis, myofibroblast differentiation and 
matrix deposition (Soo et al., 2000). Conversely, TGF-β3 has been shown to reduce 
fibroproliferative effects (Bayat et al., 2005). The role of TGF-β receptors has been 
investigated with an elevated TGFβ Receptor I: TGFβ Receptor II shown to 
increase fibroblast collagen production in vitro (Pannu et al., 2004). Despite this, 
therapies targeting TGF-β in order to reduce scarring have not been shown to be 
effective. 
 
1.7.4.2 Extracellular matrix 
 
 
After injury, changes in the composition, organization and tension of the ECM are 
integral to the regulation of wound healing. ECM tension stimulates fibroblast 
development of stress fibres (Hinz, 2010). These stress fibres are initially 
composed of cytoplasmic actins (Hinz & Gabbiani, 2010; Tomasek et al., 2002. 
With increasing ECM tension, α-smooth muscle actin (αSMA) is expressed, which 
marks the phenotypic transition from fibroblast to myofibroblast, the key cell type 
implicated in hypertrophic scarring {Tomasek et al., 2002) 
 
For this reason, a considerable focus of hypertrophic scarring research has 






In particular, interest has focused on how fibroblasts detect changes in the ECM 
and the effects this has for fibroblast phenotype. 
 
Integrins are the main receptor mediating fibroblast attachment to fibronectin 
and collagens and promote adhesive signalling through the recruitment and 
activation of specific cytosolic proteins, for example focal adhesion kinase (FAK) 
(Lagares et al., 2012). Fibroblasts in hypertrophic scars have a higher percentage 
of α1 integrin compared to normal skin. This difference no longer exists after 
serial culture, suggesting the dermal microenvironment maintains this population 
(Szulgit et al., 2002). β1 integrin is also overexpressed in fibrotic fibroblasts and a 
neutralising β1 integrin antibody reverses their excessive adhesion and 
contraction (Shi-Wen et al., 2007). A β1-integrin knockout mouse reduces 
development of fibrosis in a mouse model of skin fibrosis (Liu et al., 2009; Liu et 
al., 2010). It has recently been shown that specifically blocking TGF-1 mediated 
differentiation of myofibroblasts by preventing v integrin activation of latent 
TGF- prevents fibroproliferation in murine models of liver and lung fibrosis 
(Smith et al., 2016). 
 
As mentioned, FAK is important in mediating integrin signalling. It is also thought 
to participate in transduction pathways activated by growth factors via G-protein- 
coupled receptors and tyrosine kinases (Sieg et al., 2000). In this way, FAK is 
postulated to integrate signals from pro-fibrotic factors such as endothelin (ET- 
1), connective tissue growth factor (CTGF) or TGFβ1 (Daher et al., 2008; Liu et al., 
2007; Tan et al., 2009; Teixeira et al., 1999; Thannickal et al., 2003). 






induced fibrosis and FAK has been shown to be required for acquisition of a 
contractile phenotype in vitro (Lagares et al., 2012). Similarly, genetic knockout 
or pharmacological inhibition of FAK has been shown to reduce scarring in a 
tension induced model of hypertrophic scarring (Wong et al., 2012). 
 
Hic-5 is a focal adhesion protein that is induced by TGF-β and H2O2 which may 
shuttle to the nucleus to serve as a transcription factor (Shibanuma et al., 1994). 
It has homology to paxillin and can interact with FAK and vinculin (Thomas et al., 
1999). Hic-5 has been implicated in an autocrine loop that produces and activates 
TGF-β1 which points to an important role in the regulation of myofibroblast 
proliferation 
 
1.7.4.3 Keratinocyte fibroblast interaction 
 
 
Keratinocytes have been shown to regulate fibroblasts through secretion, 
activation, inhibition of growth factors such as TGF β. Co-culture of hypertrophic 
scar keratinocytes and fibroblasts led to change in fibroblast phenotype to 
myofibroblast (Desmouliere et al., 2005). 
 
1.7.4.4 Reversibility of fibrosis 
 
It is known from the natural history of hypertrophic scarring that the 
characteristic changes are reversible. Findings from liver fibrosis show dynamic 
interaction between matric metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs), with increased levels of TIMPs associated with 






present. Therefore research into source and identity of key MMP mediators in 
fibroproliferation may be important to reverse fibrosis (Duffield et al., 2005; Issa 
et al., 2004). 
 
1.8 Pre-clinical models of 
hypertrophic scarring 
Development of an appropriate animal model of hypertrophic scarring has been 
problematic (Aarabi et al., 2007). This is due in part to the fundamental 
differences in wound healing between humans and other mammals, particularly 
the small animals commonly used for preclinical research. In contradistinction to 
humans, the skin of small mammals has denser hair cover with a short growth 
cycle; lacks dermal papillae/apocrine gland; and has a full panniculus carnosus, 
which rapidly apposes wound edges after wounding (Wong et al., 2011). 
 
In vitro techniques have provided useful insights, but are limited by their 
inadequacy in modelling the vast complexities of the in vitro milieu, including the 
presence of various cells types, cytokines and three dimensional ECM 
architecture. Furthermore, phenotype changes seen in cells cultured from 
hypertrophic scars often do not persist after initial passages (Larsson et al., 
2008; Sargent & Whitfield, 2011). 
 
 
Research using ex vivo hypertrophic scar tissue may yield information on scar 






difficult to obtain. Firstly, clinical diagnosis of hypertrophic scarring is highly 
arbitrary and varies from institution to institution (Lee et al., 2004). Furthermore, 
tissue samples are only available when it is deemed necessary for scars to be 
excised as part of a patient’s clinical management. Developing or immature 
hypertrophic scars are rarely excised as this can trigger further hypertrophic 
scarring. Thus, samples usually represent an end stage of the scarring process and 
will yield no information about the process of scar development. 
 
Thus, it is apparent that a valid animal model is needed to further research into 







Tight skin mouse 1 and 2 (Tsk1/2) 
 
 
These genetic models were both originally developed to study systemic sclerosis, 
and have been used to test new anti-scarring therapies (Baxter et al., 2005). Tsk1 
are bred with a partial in-frame duplication of the fibrillin-1 gene, located on 
mouse chromosome 2 (Baxter et al., 2005). Tsk2 contains a gain of function 
missense mutation in Col3a1 on chromosome 1 (Christner et al., 1995). Both 
models develop tightness of the dorsal skin, thickened dermis and with increased 
collagen content. However, neither of these models adequately model the 
excessive fibroproliferation or inflammation that characterizes hypertrophic 












The Duroc pig displays similar scarring properties to the human (Goodwin et al., 
1976; Zhu et al., 2003). If dermal wounds are allowed to heal, they will display 
raised, firm, hyperpigmented scars. Histological analysis reveals increased dermal 
thickness, with increased myofibroblasts, mast cells as well as collagen whorls and 
nodules (Harunari et al., 2006). This is associated with increased TGF-1 
expression and increased collagen-1 and collagen-3. For these reasons, the Duroc 
pig is proposed as the most appropriate animal model to study hypertrophic 
scarring (Zhu et al., 2008). Unfortunately this is offset by the expense, housing and 
handling difficulties of such a large animal. 
 
Rabbit ear model 
 
 
The rabbit ear model involves the creation of a wound on the ventral surface of 
the rabbit ear, which forms a scar over 3-4 weeks post wounding (Joseph & Dyson, 
1966). Histology of the resulting scar reveals some of the features that 
characterize human hypertrophic scars, such as parallel collagen fibres and 
increased inflammation. However, the extent of this increased scarring does not 
approach that observed in hypertrophic scarring (Wells et al., 2016). 
 






Horses are well known to develop hypergranulation scar type lesions on their 
extremities, often following trauma (Theoret et al., 2013). Histological analysis of 
these lesions reveals increased haphazardly arranged collagen as well as 
increased myofibroblasts (Theoret et al., 2013). Limited literature on these scars 
points to their similarity to human hypertophic or keloid scars, but further 






Xenograft models have utilized immune deficient mice(Escamez et al., 2004; 
Kischer et al., 1989) and rats (Polo et al., 1998), such as the athymic nude mouse 
in order to receive grafts of explanted human hypertrophic scars or keloids. This 
has the advantage of studying human tissue in an in vivo environment. Xenografts 
are viable for weeks to months after transplantation and show ongoing 
angiogenesis and continued collagen production (Kischer et al., 1989). Xenograft 
models present a preformed hypertrophic scar, and thus are unable to yield 
information about the fibroproliferative process in scar development. 
Furthermore, by manipulating the immune system, key inflammatory processes 
contributing to scar formation may be being altered (Seo et al., 2013). 
 
Wound tension model 
 
 
Mouse models have employed wound tension, a well-known risk factor for 






a craniofacial distraction screw to apply a constant force across an incisional 
wound (Aarabi et al., 2007). Resulting scars bear many of the hallmarks of 
hypertrophic scarring. The main drawback of this model is the technical difficult 










1.9 Research Aims and Hypothesis 
 
Hypertrophic scarring is an area of unmet clinical need that carries a significant 
burden of disease. Our understanding of the pathogenesis of hypertrophic 
scarring is limited and this has hampered the development of novel anti-scarring 
therapies. Flii I has been established as an important regulator of wound healing 
via effects on cell migration and proliferation (Adams et al., 2009; Cowin et al., 
2007). Furthermore, as a member of the gelsolin family of proteins, Flii is 
involved in the regulation of the actin cytoskeleton, a key process in wound 
healing and scar formation. Thus, the aim of this thesis was to investigate the 
potential role of Flii in the fibroproliferative process that leads to hypertrophic 
scarring. The aims of this thesis were: 
 
1. To investigate the expression of Flii in normal human tissue, acute burns, 
immature hypertrophic scars and mature hypertrophic scars 
2. To develop and validate a murine model of hypertrophic scarring 
 
3. To determine the effect of differential expression of Flii on fibrosis and 
scarring using a murine model of hypertrophic scarring 
4. To investigate the effect of the differential expression of Flii on fibroblast 
phenotype in vitro. 
 
Studies presented in this thesis have identified a role for Flii protein in 






through modulating fibroblast phenotype. This identifies Flii as a potential 
therapeutic target for the development of novel therapies for the prevention or 


























2.1.1 Molecular Reagents 
Water Soluble Tetrazolium Salt-1 (WST-1) was purchased from Roche 
Diagnostics, NSW, Australia. 4′,6-Diamidino-2-phenylindole dihydrochloride 
(DAPI) nuclear stain used in immunocytochemistry were purchased from Sigma- 
Aldrich, Sydney, Australia. IgG from rabbit serum (#15006) used as a control and 
Ultrapure Bovine Collagen Solution (C4243) used for a floating collagen gel 
contraction assay were all purchased from Sigma-Aldrich, Sydney, Australia. 
Bleomycin sulphate (R-42569) was obtained from Hospira (Mulgrave North, VIC). 
 
2.1.2 Immunohistochemical reagents 
 
 
All the antibody information including suppliers, catalogue numbers and 
concentrations used for immunohistochemistry and western blotting analysis in 
this thesis are outlined in Table 2.1. Rabbit monoclonal anti-collagen-1 (600-401- 
103-0.5) and anti-collagen-3 (600-401-105-0.1 antibodies) were obtained from 
Rockland (Gilbertsville, PA). Anti-collagen-1 and anti-collagen-3 antibodies are 
raised against collagen-1 and collagen-3 from human and bovine placenta 
respectively. Mouse anti- Flightless I antibody is raised against amino acids 1–300 
mapping at the N terminus of Flightless I of human origin (Santa-Cruz, CA). 
 
Rabbit polyclonal anti-TGF-β1 IgG antibody (sc-146) was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA). Anti-TGF-β1 is mapped against the C- 
terminus of TGF-β1 of human origin. Mouse monoclonal anti-α-smooth muscle 





actin (αSMA) IgG antibody (A2547) was obtained from Sigma (St. Louis, MO). 
Mouse monoclonal anti-αSMA is raised against the single isoform, α-actin. 
Secondary goat anti-rabbit (A-11034) and goat anti-mouse (A-11001) Alexa Fluor 
488 antibodies were obtained from Life Technologies (Carlsbad, CA). Murine IgG 
irrelevant antibody (I8765) was obtained from Sigma (St. Louis, MO). 4', 6- 
diamidino-2-phenylindole (DAPI, D9564) was obtained from Sigma Aldrich (St. 
Louis, MO). Antibody to β-tubulin was obtained from Sigma Aldrich (St. Louis, 
MO). 
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Methods & Materials 
 
 
Antibody Manufacturer Cat # Raised In Concentration for IHC Concentration 
for Western 
Blot 
β-Tubulin Sigma Aldrich T4026 Mouse N/A 1μg/ml 
DAPI Sigma Aldrich D9564 N/A 2μg/ml N/A 
Flightless Santa Cruz 
sc- 
30046 
Rabbit 2μg/ml 1μg/ml 
Flightless Santa Cruz 
sc- 
21716 
Mouse 2μg/ml 1μg/ml 



























TGF-β1 Santa Cruz sc-146 Rabbit 2μg/ml 1μg/ml 
αSMA Sigma Aldrich A2547 Mouse 2μg/ml 1μg/ml 
2° Anti-rabbit Alexa Fluor 488 Invitrogen A11008 Goat 2μg/ml N/A 
2° Anti-goat Alexa Fluor 488 Invitrogen A11055 Donkey 2μg/ml N/A 
 












































Table 2.1 Antibody information and concentrations used in Western Blot 
analysis and 
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2.1.3 General reagents 
 
Bleomycin sulphate (R-42569, Hospira Mulgrave North, VIC) was sourced from 
the Women’s and Children’s Hospital pharmacy. It was stored and handled in 
keeping with protocols developed by the pharmacy and the Paediatric Oncology 
Unit at the Women’s and Children’s Hospital 
 
2.1.4 Osmotic pumps 
 
Alzet micro-osmotic pumps (Model 1004, Durect Corp., Cupertino CA 95014) 
were used. These are miniature implantable pumps for use in laboratory 
animals (Figure 2.1). The micro-osmotic pump has a capacity of 90µl delivers 
solutions continuously for 28 days at a consistent flow rate of 0.11µl/hour 





Figure 2.1 Alzet micro-osmotic pump (Model 1004, Durect Corp., Cupertino CA 
95014) 
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2.1.5 Human Samples 
 
Samples of normal human skin, acute burns and hypertrophic scars were obtained 
from the Royal Adelaide Hospital Adult Burns’ Unit with ethics approval from the 
Royal Adelaide Hospital Human Research Ethics’ Committee in accordance with 
the Declaration of Helsinki principles (RAH HREC Protocol 100513a). Written 
consent was obtained from patients undergoing surgery to obtain excised tissue 
that would otherwise be disposed of. 
 
Samples of hypertrophic scars and keloid scars were obtained from Dr. Michelle 
Lodge, Mr. Roger Woods and Dr. Amy Jeeves from the Women’s and Children’s 
Hospital Burns’ Unit with ethics approval from the Women’s and Children’s Health 
Network Ethics Committee in accordance with the Declaration of Helsinki 
principles (REC2399/8/14). Samples were obtained from patients undergoing 
emergency surgery for acute burns or elective surgery for treatment of burn 
related complications. 
 
Samples of neonatal foreskins were obtained from five-day old males undergoing 
elective circumcision by Paediatric surgeon Mr. Chris Kirby in his private rooms 
at Memorial Hospital, with ethics approval from the Adelaide University Ethics 
Committee and Women’s and Children’s Health Network Ethics Committee (H- 
080-2011). 
 
Normal abdominal tissue was obtained from Plastic surgeon Dr. Michelle Lodge 
from patients undergoing elective abdominoplasty at Calvary Hospital, with ethics 
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approval from the Calvary Hospital Research Ethics Committee and the Women’s 
and Children’s Health Network Ethics Committee (11-CHREC-F007). 
 
The basic design and purpose of the research project was explained 
patients/guardians as well as protocols for the storage, processing and disposal of 
tissue. Any questions were answered and, if patients agreed to participate, written 
consent was obtained. Tissue collection had no bearing on surgical technique and 
only tissue that would ordinarily be disposed of was collected. Basic medical 
history was recorded e.g. age, sex, site of surgery, details of burn (if applicable), 
skin type and co-morbidities. Samples were de-identified. 
 
2.1.6 Animal Tissue 
 
 
All mouse strains in this study were BALB/c congenic and were maintained as 
homozygous colonies or by continuous backcross to BALB/c animals. Wild-type 
controls were obtained from BALB/c inbred litters. The murine alleles of Flii used 
in this study were: 
 
1. Flii t m1H d c (MGI:2 179 825), a targeted null allele of Flii 
(Campbell et al. 2002). The genotype of a heterozygous carrier of this 
allele is written as Flii +/− ; and 
 
2. Tg(FLII)1Hdc (MGI:3 796 828), a transgenic strain expressing 
exogenous human Flii due to the insertion of the human cosmid clone 
c110H8 (Campbell et al. 2002).These animals carry two copies of the 
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mouse Flii gene and two copies of the human Flii transgene (Flii+/+; 
FliiTg/Tg) (Campbell et al. 2002). 
 
Flii+/- and FliiTg/Tg were generated by our collaborators (see 2.1.5.1), Dr. Hugh 
Campbell and A/Prof Ruth Arkell from Early Mammalian Development 
Laboratory, Research School of Biology, ANU College of Medicine, Biology & 
Environment, ACT, Australia (Figure 2.2). Balb/c wildtype mice were produced as 
litter mates to the Flii+/- mice as a result of cross breeding heterozygous male mice 
to wild type female mice. 
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Figure 2.2: Targeted disruption of the Flii gene. A Schematic representation of 
the domain structure of the targeting vector, relevant portion of the Flii gene and 
the targeted allele after homologous recombination. . * indicates the BspEI site in 
exon 5 introduced by site-directed mutagenesis. Flii exons are represented by 
numbered open boxes. B Triple-primer PCR showing wild-type (210bp) and 
mutant (538bp) products. Animals with one copy of each wild-type and mutant 
allele express no more than 50% of regular Flii expression (Campbell et al., 2002). 
C The cosmid clone used to generate FliiTg/Tg mice. The cosmid contains the Flii 
gene, SMCR7 gene, and partial codes for TOP3A and LLGL1 genes. Figure adapted 
from (Thomsen et al., 2011). 
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2.1.6.1 Flii+/- Mouse Generation 
Flii+/- mice were generated by a positive/negative selection strategy and 
homologous recombination of a null allele of the mouse Flii gene into embryonic 
stem cells. The regions involved in this recombination only involve Flii so that 
changes will only affect the Flii gene. The resulting mice contain one normal copy 
and one mutant copy of the Flii gene, resulting in ubiquitous expression of Flii at 
no more than 50%. Flii deficient homozygotes do not survive embryogenesis. 
Homozygous Flii mutant blastocysts hatch, attach and form an outer growing 
trophoblast cell layer, but egg cylinder formation fails and embryos are non-viable 
by embryonic day 7 (Thomsen et al., 2011). 
 
The strain was maintained by cross breeding of Flii+/- carriers to Balb/c mice, 
which produced offspring of approximately 50% Flii+/- and 50% Balb/C (wild type 
(WT)) (Campbell et al., 2002). 
 
A three primer multiplex reaction was used to detect WT and Flii+/- alleles in a 
positive/positive PCR assay. PCR was performed on DNA extracted from 5mm tail 
snips of 25 day old Flii+/- x Balb/C offspring (see Figure 2.1B). 
 
2.1.6.2 FliiTg/Tg Mouse Generation 
 
Mice carrying additional copies of the Flii gene were generated by introduction of 
a human cosmid clone (c110H8) containing the entire Flii locus into the mouse 
genome using transgenesis. The extent of the construct was characterised using 
restriction mapping (Figure 2.1). The availability of the mouse genome allowed 
for the estimation of the extent of the cosmid. Currently, it is known that the 
cosmid contains all of the neighbouring Smith-Magenis syndrome chromosome 
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region candidate 7 homolog (SMCR7) gene as well as patrial coding sequence for 
the Topoisomerase (DNA) III alpha (TOPA3A) and Lethal giant larve homolog 
(LLGL1) genes however we have conducted extensive studies characterising our 
different transgenic mice to ensure that the effects on wound healing are 
attributed to Flii gene alone (Thomsen et al., 2011). This was achieved by making 
a second transgenic strain using only a 17.8kb BspH1 sub-fragment of the cosmid) 
and assessing the strain to determine whether this minimal construct is able to 
provide all functions of endogenous Flii gene. We have shown that this construct 
contains all necessary elements to recapitulate the function of endogenous Flii and 
that Flii protein levels are sufficiently elevated (up to 1.52 times WT level) to 
cause altered Flii function in these mice (Thomsen et al., 2011). 
 
The transgenic strain used in this project was backcrossed to BALB/c animals for 
 
10 generations before being intercrossed and homozygous animals were 
classified via progeny testing following established protocols. The mouse colony 
was subsequently maintained by intercross of animals homozygous for the 
transgene. These animals carry two copies of the mouse Flii gene and two copies 
of the human Flii were out-crossed to BALB/c animals to generate the progeny 
that carry two copies of the mouse Flii gene and one copy of the human Flii 
transgene. A two primer reaction was been designed to detect both the mouse Flii 
allele and the human Flii allele in a positive/positive PCR assay. The two primers 
used in which the sequence of each primer is identical between mouse and human, 
but differences in the intervening regions generate two distinct size products. The 
PCR was performed on DNA extracted from 5mm tail snips from approximately 
25 day old FliiTg/Tg. 
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2.1.6.3 FnAb Monoclonal Antibody Generation 
 
FnAb was produced in the Cowin laboratory using standard protocols. Female 
mice were injected with synthetic peptides in PBS and Freund’s complete 
adjuvant. After the initial immunisation, this injection was given weekly for 4 
weeks. 35 days post immunisation, 100µL of blood was sampled and analysed for 
antibody levels. Mice showing a low antibody titre were given a booster 
immunization. All mice were euthanized at day 90 post primary immunization and 
spleens were harvested for fusion. 
 
Spleens were disrupted by injection of RF10 media and connective tissue was 
removed. Cell suspension was agitated and cells pelleted at 400G for 5 minutes. 
Pellets were resuspended in 5ml red cell lysis buffer and re-pelleted under the 
same conditions. Cells were then resuspended in RF10 media and counted. 
Myeloma cells were added to the spleen cells at a ratio of 10:1 
splenocytes:myelocytes. Cells were pelleted again, supernatant was removed and 
cells were resuspended in 1ml PEG. 3ml of RF 10 was added dropwise over 10 
minutes, then a further 7ml RF10 dropwise over 10 minutes. Cells were then re- 
pelleted and resuspended in 50ml HAT media, sorted using FACS and plated onto 
a 96 well plate. The cells were left for 72 hours and culture media was then tested 
by ELISA for Flii reactivity and by Isostrip for IgG isoforms. Those testing positive 
for both Flii and IgG were expanded, purified and tested in mouse incisional 
wounds for an improvement in wound healing compared to an irrelevant IgG 
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The following experimental methods were used in this study. The methods were 
adapted or modified from different published studies as stated in the text or 
referenced in the text. 
 
2.2.1 A novel murine model of hypertrophic scarring using sub- 
cutaneous infusion of bleomycin 
We have adapted the dosage, delivery and temporal characteristics of this model 
in order to develop a novel model of hypertrophic scarring. Bleomycin is 
delivered continuously via a subcutaneous osmotic pump (Alzet Model 1004, 
Durect Corp., Cupertino CA 95014) in order to stimulate a fibroproliferative 
process in contrast to the sclerotic process described by Yamamoto et al 
(Yamamoto et al., 1999). Bleomycin infusion provides a continuous 
inflammatory stimulus, rather than the intermittent stimulus in Yamamoto model. 
Mice were euthanized at 28-days or 56-days in an attempt to model both 
immature and mature hypertrophic scars. 
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Fig. 2.3 Murine model of hypertrophic scarring using subcutaneous 




2.2.2 Murine Surgery 
All experiments were approved by the Women’s and Children’s Health Service 
Animal Care and Ethics Committee and the ANU Animal Ethics Committee 
following the Australian Code of Practice for the Care and the Use of Animals for 
Scientific Purposes (WCHN AEC#892). Mice were housed in Women’s and 
Children’s Hospital animal house where cages were cleaned and food and water 
replaced daily. 
 
Prior to surgery osmotic pumps (Alzet Model 1004, Durect Corp., Cupertino CA 
95014) were filled to their 90µl capacity with 2.8mg/ml bleomycin sulphate (R- 
42569, Hospira Mulgrave North, VIC) or a sterile control solution of phosphate 
buffered saline (PBS). Pumps are designed to produce a consistent rate of flow of 
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0.11µl/hour for 28 days. Pumps were weighed before and after filling to ensure 
correct volume. Mice were anaesthetised using gaseous isofluorane, 5% 
induction, 2% maintenance. The dorsum of the mice was shaved and cleaned with 
10% povidine iodine solution. A 0.5cm transverse incision was made across the 
midline at a point approximately 4 cm caudal to the base of the skull. Using blunt 
dissection, a pocket was made between the skin and muscle layers into which the 
osmotic pump was inserted. This pocket was carefully dissected in a suprafascial 
plane to ensure that pumps would not migrate from their original location. 
Wounds were closed with 4-0 prolene and secured with tissue adhesive 
(Histoacryl, TissueSeal, Ann Arbor, Michigan) (Figure 2.3). Mice were euthanized 
at 28 days or 56 days after pump insertion and a 4cm x 1.5cm area of skin was 
excised at a location corresponding to the cranial end of the osmotic pump. 
Unwounded skin was collected from each mouse group. 
 
Mice were weighed upon arrival, prior to surgery and post-surgery at time points 
stated above to monitor their wellbeing. Mice that lost more than 10% of the body 
weight were excluded from the study. Mouse behaviour, coat appearance and 
movements were also observed regularly to ensure no adverse effects from 
surgery. 
 
At the designated day of sacrifice (day 28 or day 56), the mice were weighed and 
euthanized using CO2 and cervical dislocation. The mice were then re-shaved and 
digital photographs of the wounds were taken prior to excision. A 4cm x 1.5cm 
area of skin was excised around the fibrotic lesions at a location corresponding to 
the cranial end of the osmotic pump and unwounded skin was collected from each 
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mouse group/Both left and right wounds were excised and bisected, half was used 
for histological analyses and the other half was snap-frozen in liquid nitrogen and 
stored at -80°C for biochemical analyses. For each mouse group, lung, live and 
kidney were also collected 
 
2.2.3 Flii neutralising antibody treatment 
 
In a subset of WT female 12-week old mice (n=6) 200l of 50l/ml FnAb was 
injected subcutaneously at the cranial end of the osmotic pump on days 0, 7, 14 
and 21. The 50l/ml dose of FnAb had previously been used for treating acute 
injuries, burns and diabetic wound in murine and porcine models (J. E. Jackson et 
al., 2012; Kopecki, Ruzehaji, et al., 2013; Ruzehaji, Kopecki, et al., 2013). Fibrotic 
lesions and unwounded skin from all animals were collected at day 28 post 
osmotic pump insertion and bisected and fixed in 10% buffered formalin for 
histology and immunohistochemistry. 
 
2.2.4 Sample processing, histology and immunohistochemistry 
 
 
Human and murine samples collected from surgery were fixed in 10% formalin 
overnight, followed by processing in a Leica TP1020 tissue processor which 
dehydrated the tissues in a graded alcohol series (70% for 120 mins, 80% for 60 
mins, 90% for 105 mins and 100% for 240 mins). They were then cleared in 
transitional solvent xylene for 180 mins followed by 240 mins of tissue infiltration 
with paraffin wax. Serial tissue sections (4μm) were cut from paraffin-embedded 
fixed tissue using a Leica RM2235 microtome and labelled. Prior to staining, skin 
sections were de-waxed by a series of xylene (30 mins) and graduated ethanol 
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washes (bringing sections to water) (100% for 1 min, 70% for 1 min & 30% for 1 
min) before further processing. Skin sections were either stained with 
Haematoxylin and Eosin (H&E), Masson’s Trichrome or subjected to antigen 
retrieval and immunohistochemistry using antibodies from Table 2.1. Staining the 
sections in H&E involved bringing sections to water as mentioned above, followed 
by staining in Lillie’s- Mayer’s Haematoxylin for 6min, “blueing” sections in 
bicarbonate water for 15 seconds, differentiating Haematoxylin in 0.25% Acid 
Alcohol for 6 sec, staining in alcohol based Eosin stain for 2 minutes dehydrating 
in grated alcohol series (30% for 30 sec, 70% for 30 seconds, 100% for 1 min) and 
clearing in transitional solvent xylene for 2 minutes before mounting in DePeX 
mounting medium. 
 
H&E staining of unwounded skin was analysed microscopically using light 
microscopy. Dermal thickness was determined by measuring the distance 
between the basement membrane and the panniculus carnosus using Image Pro- 
Plus 5.1 program (MediaCyberneticsInc.). Epidermal thickness was measured as 
the distance from the stratum corneum to the basement membrane. Multiple 
measurements were taken across the width of the sections and the average of 
these was calculated. This was done in a blinded fashion. For sections showing 
fibrotic pathology dermal thickness measurements only included fibrotic 
regions. The limits of fibrotic regions were determined by the presence/absence 
of dermal thickening, dermal appendages, epidermal thickening and epidermal 
acanthosis. H&E stained wounds from Flii+/-, WT and FliiTg/Tg mice were analysed 
using light microscopy and fibrotic cross sectional area was measured using the 
Image  Pro-Plus program.   Serial sections 
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were examined until the region of maximal thickness/cross sectional area was 
found. These sections were used for final measurements. 
 
2.2.5 Immunohistochemistry and image analysis 
 
Immunohistochemistry experiments were undertaken on all human and murine 
samples. The following method was used as the standard antigen retrieval 
procedure, and Table 2.1 lists all the primary and secondary antibodies used in 
immunohistochemistry for different targets. 
 
Sections were de-waxed by a series of xylene changes (30 minutes) and gradual 
ethanol washes (100% for 1 min, 70% for 1 minute and 30% for 1 minute), before 
being rinsed in 1x Phosphate Buffered Saline (PBS) and pre-treated with 250 ml 
Target Retrieval Solution (TRS) solution (2.8g Citric Acid, 3.76g Glycine, 0.372g 
EDTA, pH 5.9 in 1L 1xPBS). The sections were then microwaved for 2 minutes on 
“high” after which a “ballast” pot of water was added to help absorb some heat and 
pre-treatment continued for 2 x 5 minutes with regular “airing” to let the steam 
out and ensure that temperature reached 94°C but not 100°C. Sections were then 
allowed to cool to 50°C on the bench before they were washed in fresh 1x PBS and 
enzyme digested with 0.0625g of Trypsin (Sigma-Aldrich, Sydney, Australia) 
dissolved in 1xPBS and pre-warmed to 37°C. Following the 3 min enzyme 
digestion at 37°C, sections were washed in 1xPBS and then incubated for 30 
minutes in NHS blocking solution (3%NHS in 1xPBS). Slides were then washed in 
1xPBS for 2 min and then incubated in primary antibody in a humid air tight box 
overnight at 4°C. Sections were then washed 3 x 2 minutes in 1xPBS and then 
incubated in species specific Alexa Fluor 488 or Alex Fluor 594 at a concentration 
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of 2µg/ml for all primary antibodies (Table 2.1) for 1hr at room temperature in a 
humid box. Slides were then washed 3 x 2 minutes in 1xPBS to remove any 
unspecific binding of Alex Fluor and mounted in Dako Fluorescent Mounting 
Medium (DAKO Corporation, Botany, Australia). Slides were stored in the dark at 
-20°C. Integrated fluorescence intensity was determined using AnalySIS software 
package (Soft- Imaging System GmbH, Munster, Germany) (Cowin et al., 2007). 
Negative controls were included to demonstrate antibody staining specificity. 
Control samples undergo the exact same staining procedure outlined except 
omitting the primary or secondary antibody. All control sections had negligible 
immunofluorescence. 
 
2.2.6 Cell lines and cell culture 
 
Cells used in cell culture experiments were human foreskin fibroblasts (HFFs) and 
primary murine fibroblasts (from Flii+/-, WT and FliiTg/Tg mice). All cell cultures 
were incubated at 37o C and 5% CO2. Cells were serum starved in DMEM (JRH 
Biosciences, USA) for at least 12 hrs or as otherwise stated prior to the start of 
experimenting to synchronize the cells to the same phase of cell cycle. Cells were 
stored in liquid nitrogen stores in 10% heat inactivated Fetal Calf Serum (FCS) 
(JRH Biosciences, USA) in DMEM containing following antibiotics unless otherwise 
stated: 100U/ml penicillin, 100μg/ml streptomycin and 100μg/ml Fungizone 
(Invitrogen, Mount Waverly, VIC, Australia). Cells were grown in the same 10% 
heat inactivated FCS solution. 
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2.2.7 HFF isolation and culture 
 
Neonatal foreskins were obtained following elective circumcision performed on 
five day old males by paediatric surgeon Mr Chris Kirby and placed immediately 
into ice cold Ham’s Nutrient Mixture F12 (SAFC Biosciences, Lenexa, KS), 
containing 100U/ml pencillin, 100μg/ml streptomycin and 100μg/ml Fungizone. 
A 5mm punch biopsy was used to excise explants in sterile conditions, which were 
placed dermal side down into 6-well plates. Explants were allowed to partially dry 
and fix to the bottom of the well before 2ml DMEM, 20% FCS, 100U/ml pencillin, 
100μg/ml streptomycin and 100μg/ml Fungizone was added and tissue cultured 
at 37°C, 5% CO2. Cell media was replaced after 24hr of initial explant culture and 
then every 2 days. At day 7 post explant culture once fibroblasts migrated out from 
the explant the skin explant was removed and cells cultured as normal in 10% 
FCS/DMEM, 100U/ml penicillin, 100μg/ml streptomycin and 100μg/ml 
Fungizone. Low passage cells (P 2–5) were used in all experiments. 
 
2.2.8 Murine fibroblast isolation and culture 
 
Hair was shaved from the dorsal flank of euthanized 12-week-old female BALB/c 
Flii+/-, WT, and FliiTg/Tg mice and skin excised and collected in ice-cold Ham’s 
Nutrient Mixture F12 (SAFC Biosciences, Lenexa, KS), 1% Penicillin Streptomycin, 
1% Fungizone (Sigma-Aldrich). A 5mm punch biopsy was used to excise explants 
in sterile conditions, which were placed dermal side down into 6-well plates. 
Explants were allowed to partially dry and fix to the bottom of the well before 2ml 
DMEM, 20% FCS, 100U/ml pencillin, 100μg/ml streptomycin and 100μg/ml 
Fungizone was added and tissue cultured at 37°C, 5% CO2. Cell media was 
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replaced after 24hr of initial explant culture and then every 2 days. At day 7 post 
explant culture once fibroblasts migrated out from the explant the skin explant 
was removed and cells cultured as normal in 10% FCS/DMEM, 1% Penicillin 
Streptomycin. Low passage cells (P 2–5) were used in all experiments. 
 
2.2.9 Migration scratch assay 
 
HFFs or primary murine fibroblasts were grown in 12-well plates (Cell-Tech, 
Millipore, NSW, Australia) in 10% heat inactivated FCS in DMEM containing 
100U/ml pencillin, 100μg/ml streptomycin and 100μg/ml fungizone at 37°C, 5% 
CO2. Cells were cultured with or without the addition of bleomycin 140µg/ml (see 
below) or Flii neutralising antibody (FnAb) 20 µg/ml (see below). They were then 
scratched with a P200 pipette tip, producing equal size wounds of 2 mm x 1 cm. 
The cells were photographed using the Olympus DP72 camera at 0, 3, 6, 9, 12, 24, 
30, 36, 48 and 96 hrs post-wounding and wound area was calculated using the 
cellSens digital imaging program (Olympus, Shinjuku, Japan). Reduction in 
scratch wound width was measured and recorded. This was replicated 3 times for 
each cell type and treatment 
 
2.2.10 WST-1 Proliferation Assay 
 
WST-1 Proliferation reagent (Roche Diagnostics, NSW, Australia) was used to 
assess the proliferation rate of HFFs and primary murine fibroblasts in response 
to different concentrations of bleomycin. The WST-1 is a tetrazolium salt based 
reagent that converts the soluble formazan which directly correlates with cellular 
metabolic activity and proliferation rate. Cells were seeded in 96-well microtitre 
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plates at a concentration of 1x105 cells per well in 100μl of 10% or 0.5% 
FCS/DMEM with antibiotics. One lane of a 96-well microtitre plate was filled with 
media only and one lane with normal cells, which did not receive any treatment 
or WST-1 reagent and acted as the blank controls. Cells were incubated at 37°C 
5% CO2 overnight, cell media was aspirated off and serum-free media was added 
to all cells to synchronize all cells to the gap phase of the cell cycle. After 6 hrs, 
100μl of 10% or 0.5% FCS/DMEM with antibiotics was added to the cells and cells 
were incubated overnight in 37°C 5% CO2 incubator for 24, 48 or 72 hrs depending 
on the time point of assessment. Following the incubation period, 10μl of WST-1 
reagent was added to the cells and mixed thoroughly on an orbital shaker. The 
cells were then incubated at 37°C 5% CO2 incubator for 30 min as per 
manufacturer’s instructions where metabolic enzymes produced by cells react 
with WST-1 reagent to form a formazan dye product. The amount of the formazan 
dye produced therefore directly correlates with metabolic activity of the cells and 
their proliferation rate. Formazan dye was quantified where dual absorbance of 
450nm and 600nm was measured on the Tecan microplate reader. Absorbance 
values were blanked with absorbance values of control without cells and then 
compared between different cells for the assessment of proliferation. Results were 
normalized to the untreated control sample and expressed as a percentage. 
 
2.2.11 Immunocytochemistry, image analysis and fluorescence 
co-localization 
HFFs or primary murine were grown to a density of 60-70% confluence on sterile 
glass coverslips. Cells were serum starved for 12 hours and then media was 
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exchanged for 10% FCS/DMEM, 100U/ml pencillin, 100μg/ml streptomycin and 
100μg/ml Fungizone + 140μcg/ml bleomycin sulfate. In a separate experiment, 
both control and bleomycin cells were treated with 20μg/ml FnAb or 20μg/ml 
irrelevant murine IgG (control). Cells were then incubated for 6 hours before 
being fixed and permeabilised with methanol/0.02% Tx-100/PBS using a protocol 
described by Smith-Clerc and Hinz (Smith-Clerc & Hinz, 2010). Cells were then 
blocked with bovine serum albumin for 30 minutes before incubation with 
primary antibodies against Flii or αSMA for 60 minutes. Cells were then washed 
thoroughly in 0.02% Tx-100/PBS before Flii/αSMA was detected through 
incubation with fluorescent Alex Fluor 488 goat anti-mouse IgG (2μg/ml, 
Invitrogen OR). Coverslips were mounted onto slides using Dako mounting 
medium (DAKO Corporation, Botany, Australia) and images were obtained using 
the Olympus DP72 camera and cellSens digital imaging program (Olympus, 
Shinjuku, Japan). Negative controls included replacing primary antibodies with 
species-specific IgG. For verification of staining, nonspecific binding was 
determined by omitting primary or secondary antibodies. All control sections had 
negligible immunofluorescence. 
 
2.2.12 Protein Extraction and quantification 
 
HFFs were grown until confluent in T75 flask. At this time they were serum 
starved for 24 hours, whereupon media was replaced with 10% FCS/DMEM, 5% 
Penicillin Streptomycin (control), 10% FCS/DMEM or 5% Penicillin Streptomycin 
+ 140μcg/ml bleomycin sulfate. Cells were cultured for six hours and protein was 
then extracted by lysing cells in 50 mM Tris pH 7.5, 1 mM EDTA, 50 mM NaCl, 0.5% 
Triton-X-100, containing Complete Mini protease inhibitor cocktail tablet (Roche 
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Diagnostics, Castle Hill, NSW). Protein levels were quantified using the Thermo 
Scientific Pierce Bicinchoninic Acid (BCA) Protein Assay Kit (Waltham, MA). The 
absorbance was measured at a wavelength of 570nm in a Dynatech MR700 
microplate reader using the BioLinx 2.0 computer software program. 
 
2.2.13 Western Blotting 
 
 
Protein amounts in each sample were equalized by dilution and heated at 95°C 
prior to electrophoresis. Protein fractions were run on a 10% SDS-PAGE (sodium 
dodecyl sulfate / polyacrylamide) gel consisting of a 10% separating solution 
(3.35ml 30% Acrylamide-Bis solution (37.5:1, 2.6% C, BioRad Laboratories, CA, 
USA), 1.25ml 3M Tris pH 8.9, 5.25ml distilled water, 125μl 10% SDS, 100μl 10% 
APS (Ammonium Persulfate)(Sigma-Aldrich Chemical Company, Sydney, 
Australia) and 6.25μl TEMED(N,N,N’,N’-Tetramethylethylene-diamine)(Sigma- 
Aldrich Chemical Company, Sydney, Australia) and 4% stacking solution (0.5ml 
30% Acrylamide, 0.276ml 0.5M Tris pH 6.8, 4.104ml distilled water, 50μl 10% SDS, 
40μl 10% APS and 4μl TEMED). Protein fractions were run at 100V for 90 min in 
the electrophoresis tank. The gel was then transferred onto a 0.2μm pore 
nitrocellulose membrane (Advantec MFS Inc, CA, USA) by the process of Wet 
Transfer using the Bio-Rad Mini-ProteanII Transfer Apparatus (Bio- Rad 
Laboratories, NSW, Australia) and 1xWet Transfer Buffer/Tobins Buffer (3.3g Tris, 
14.4g Glycine, 900ml MilliQ Water, 100ml Methanol) at 100V for 1 hr. 
 
Membranes were then blocked in 5% skimmed milk in 0.3% Tween/PBS for 1hr 
 
and  hybridized  with  appropriate  primary  antibody  at  1μg/ml  concentration, 
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diluted in blocking buffer prior to addition to the membrane overnight at 4°C. This 
was followed by 4 x 10 min membrane washes in 5% skim milk, 0.3% Tween/PBS 
blocking buffer and application of appropriate secondary antibody conjugated to 
horse radish peroxidise (HRP) at 1μg/ml and diluted in blocking buffer and 
applied to membranes in dark for 1 hr at room temperature. This was followed by 
further membrane washes of 4 x 10 min in 0.3% Tween/PBS and signal detection 
using Super Signal West Femto Maximum Sensitivity Substrate (Pierce 
Biotechnology, Rockford, USA) and signal capture using GeneSnap analysis 
software program (Syngene, Maryland, USA). Membranes were stripped by 
incubation in Stripping Buffer (5ml 20% SDS, 350μl 2-Mercaptoethanol (#M7522, 
Sigma- Aldrich, Sydney, Australia) , 6.25ml 0.5M Tris/HCl pH 6.7, 38.4ml MilliQ 
Water) for 30 min with gentle shaking every 10 min followed by re-probing of 
membranes with β-tubulin (Sigma-Aldrich, Sydney, Australia) as a 
loading/transfer control. 
 
2.3 Statistical analysis 
 
Statistical differences were determined using the InStat program v3.05 (GraphPad 
Software, USA) using the unpaired Student’s t-test or ANOVA. For data not 
following a normal distribution, the Mann-Whitney U test was performed. A P 














Parts of this chapter have been published in following journal: 
 
Cameron A.M., Ruzehaji, N. Cowin A.J. (2010). Burn wound 




Cameron A.M., Turner C.T., Adams D.H., Jackson J.E., Melville E, 
Arkell R.M., Anderson P.J and Cowin A.J. (2016) Flightless I is a 
key regulator of the fibroproliferative process in hypertrophic 
scarring and a target for a novel anti-scarring therapy Br J 
Dermatol 174(4): 786-794 
EXPRESSION OF FLIGHTLESS IN 
HUMAN BURNS AND 
HYPERTROPHIC SCARS 







Hypertrophic scarring is a fibroproliferative disease of the skin most commonly 
associated with burn injury, but may also occur after trauma or elective 
surgery(Aarabi et al., 2007; Engrav et al., 2007). It is estimated that at least 70% 
of deep burns in adults, and a greater percentage in children, will develop 
hypertrophic scarring, which can cause disfigurement (Robson et al., 2001). 
 
Hypertrophic scarring represents an aberration of the normal wound healing 
process, which is a tightly orchestrated, nonlinear sequence involving numerous 
cell types, extracellular matrix (ECM) components and signaling molecules 
(Bielefeld et al., 2013). Normal wound healing balances several requirements: 
prevention of infection, restoration of epithelial integrity and approximation of 
normal skin structure and function (Wynn, 2008). Hypertrophic scarring results 
from a disruption of this delicate balance. A prolonged inflammatory phase 
results in the persistence of large numbers of myofibroblasts in the wound and 
elevated levels of fibrogenic cytokines, such as transforming growth factor-β1 
(TGF- β1) and connective tissue growth factor (CTGF) (Hinz, 
2010).Myofibroblasts drive inflammation and overproduce collagen, which 
accumulates in a disorganized manner (Hayakawa et al., 1982)and results in an 
increased collagen 1/3 ratio (Rahban & Garner, 2003. This results in a raised, 
red, tender scar, which is prone to contracture over time (Rahban et al., 2003 ; 
Zhang et al., 1995). Studies have shown that the protein Flightless I (Flii) is a 
regulator of the wound healing process (Cowin et al., 2007). Flii is a member of 
the gelsolin family of actin-remodeling proteins that regulates intracellular actin 





by severing pre-existing filaments and/or capping filament ends to enable 
filament reassembly into new cytoskeletal structures (Kopecki et al., 2011). Flii 
co-localizes with molecules involved in regulating cytoskeletal reorganization, 
including members of the Rho family of GTPases, Ras and Cdc42 (Claudianos & 
Campbell, 1995). It possesses a unique leucine-rich repeat domain, which is 
important for protein–protein interactions (Campbell et al., 1993). Cells within 
the epidermis and dermis express Flii and studies have shown that Flii is able to 
translocate from the cytoplasm to the nucleus in response to wounding (Cowin 
et al., 2007). Focal adhesions and migratory structures involved in cellular 
motility also express Flii (Davy et al., 2000) and it is also secreted from cells. In 
Flii+/- mice, healing is enhanced, whereas in FliiTg/Tg mice, healing is impaired, 
with delayed epithelial migration and increased scarring (Cowin et al., 2012). In 
vitro, Flii+/- fibroblasts and keratinocytes have improved cellular adhesion and 
spreading resulting in accelerated scratch wound closure (Cowin et al., 2007; 
Kopecki et al., 2009). Additionally, reducing Flii in a murine model of partial- 
thickness burn injury led to faster re-epithelialization and reduced scar 
formation (Adams et al., 2009) suggesting the reduction of this protein in 
wounds may be beneficial as a hypertrophic scarring therapeutic treatment. 
Given the relationship between impaired wound healing and the development of 
hypertrophic scars, we have investigated whether Flii has a regulatory role in the 
fibroproliferative process that leads to hypertrophic scar formation. Here we 
examine the expression of Flii in human hypertrophic scars. 






Samples of human normal skin, acute burns and hypertrophic scars at varying 
stages of maturity were collected from the Royal Adelaide Hospital Adult Burns’ 
Unit, the Women’s and Children’s Hospital and Calvary Hospital. Normal skin 
was sourced mainly from patients undergoing abdominoplasty or occasionally 
from normal skin adjacent to scar specimens (Figure 3.1). Acute burn specimens 
were sourced from debridement of burn injuries (Figure 3.2). These 
debridements occurred at times ranging from 6 hours to 16 days post burn 
injury. Hypertrophic scars were obtained after surgery indicated for contracture 
release or scar revision (Figure 3.3). Samples were initially classified according 








Fig. 3.1 The author (left) collecting human tissue samples from the RAH 
Adult Burns’ service. 





The samples were examined as H&E sections to confirm these classifications. 
Mature hypertrophic scars demonstrated increased dermal thickness, with 
parallel sheets of collagen. Immature hypertrophic scars demonstrated collagen 
nodules and whorls in the dermis. Immature hypertrophic scars displayed marked 
epidermal hyperplasia and basal cell disarray. Mature hypertrophic scars showed 
a flattened epidermal layer with basal cell disarray and vacuolar change. It was 
also noted that there was a great deal of heterogeneity of these histological 
findings and that the histological classification of scars did not always correlate to 
their clinical classification (Figure 3.4.). 
 
 
Histological examination of acute burns showed epidermal peeling, sub epidermal 
vesicles, collagen alteration, microthrombus and coagulative necrosis. Again, 
there was a great deal of heterogeneity between the histological features of these 
samples that did not necessarily correlate with their clinical classification. 
 
Immunohistochemical analysis for Flii in the samples showed that Flii expression 
was increased in human burn wounds and hypertrophic scars compared with 
normal unwounded skin. This increase is Flii expression was seen throughout the 
epidermis and also in the dermis of acute burns and immature scars. 
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Fig. 3.2 Clinical photographs of acute burns prior to sample collection 
93 





Fig. 3.3 Clinical photographs of hypertrophic scars prior to sample 
collection 
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Fig. 3.4 Histopathological features of hypertrophic scars. Samples of 
immature hypertrophic scars and mature hypertrophic scars were stained with 
haemotoxylin and eosin and photographed at 20 or 40 times magnification. 
Mature hypertrophic scar demonstrated parallel sheets of collagen in the dermis 
(top left, arrows). Immature hypertrophic scars demonstrated collagen nodules 
and whorls (top right, arrows). Hyperplasia and basal cell disarray were seen in 
immature hypertrophic scars (bottom left, arrows). Mature hypertrophic scars 
displayed a flattened epidermal layer with basal cell disarray and vacuolar change 
(bottom right). 
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Fig. 3.5 Immunolocalisation of Flii in human skin, acute burns and 
hypertrophic scars. Flii expression was increased in human burn wounds and 
hypertrophic scars compared with normal unwounded skin. This increase in Flii 
expression was seen throughout the epidermis and also in the dermis of acute 
burns and immature scars. Scale bars = 100µm 
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Hypertrophic scars and keloids were originally defined by their clinical 
characteristics, before attempts were made to define them as distinct pathologies, 
in terms of their histological characteristics, such as parallel collagen fibres, 
collagen whorls and epidermal flattening (Lee et al., 2004). However, producing 
evidence to support these definitions has been difficult; indeed the histological 
distinction between normal scars, hypertrophic scars and keloid scars is 
controversial (Lee et al., 2004; Muyembe-Tamfum et al., 2009). There is currently 
no consensus in the literature regarding the relative contribution of different 
collagen subtypes to hypertrophic scar tissue fibrillogenesis, nor the importance 
or temporal profile of key cell types, such as myofibroblasts, or well-known 
cytokines, such as TGF-β1 (Dale et al., 1996; Fleischmajer et al., 1990; Rawlins et 
al., 2006; Umezawa, 1967). 
 
Indeed, the classification of hypertrophic versus normal scarring as distinctive 
entities may only be suited to clinical application. Defining a scar as 
“hypertrophic” ensures the patient receives treatment accordingly, such as scar 
massage, topical silicone or occasionally intralesional corticosteroid injection. 
Surgery may be indicated to release subsequent scar contracture or to improve 
appearance. 
 
The lack of objective markers for hypertrophic scarring, such as a clearly defined 
histopathological characteristics or biochemical markers, makes research using 
human samples difficult. Without accurate classification of tissue samples, 
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quantifiable data is difficult to come by. Furthermore, the types of burn injury or 
scar that may be collected are limited by the clinical indications for surgery. Viz 
only full thickness or near full thickness burns are excised. More superficial burns 
are managed without surgery. Furthermore, given the natural history of 
hypertrophic scarring, it is unusual to operate on acute hypertrophic scars, as 
most will mature over 12 months. 
 
Hence the tissue samples in this study comprised mainly full thickness burns and 
hypertrophic scars in the later stages of their development. In addition these 
tissues came from a variety of anatomical locations in a wide demographic of 
patients. For these reasons, in depth investigation of Flii levels or related 
parameters was not attempted. Although qualitative date may be taken from these 
samples, any quantitative analysis is problematic. 
 
The increase in Flii expression in acute burns and hypertrophic scars suggest Flii 
may have a role in the pathogenesis of hypertrophic scarring. Interestingly, this 
increase was seen predominately in the epidermis. The epidermis has an 
important role in normal skin, as it contain stem cell niches and participates in 
complex signaling pathways to regulate mesenchymal cell function (Aarabi et al., 
2007). Indeed, burn surgeons have long recognised the importance of achieving 
epidermal coverage of burn wounds (via autologous skin graft or otherwise) at an 
early stage of treatment in order to dampen inflammation and prevent 
hypertrophic scarring. 
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Keratinocytes have been shown to regulate fibroblasts through secretion, 
activation, inhibition of growth factors such as TGF-β. Co-culture of human 
keratinocytes and fibroblasts led to fibroblast- myofibroblast transition over 6 
days in a process regulated by the pro-scarring cytokine TGF β (Shephard et al., 
2004). Given Flii’s role in regulation of keratinocyte migration after wound 
repair(Cowin et al., 2007), regulation of TGF β in burn wound healing (Adams et 
al., 2009) and key role in epithelial integrity (Kopecki et al., 2009) there is a 
putative role for Flii in this epidermal regulation of mesenchymal activity. 
 
In addition a number of recent studies have provided compelling evidence that Flii 
has an important role as an immune-modulator (Dai et al., 2009; Hayashi et al., 
2010; Lei et al., 2012; Li et al., 2008). Flii’s N-terminus LRR domains share nearly 
50% homology to the LRR domains of toll-like receptor-4 (TLR-4). TLRs function 
as detectors of injury or infection by binding to pathogen-associated molecular 
patterns molecules (PAMPs) (e.g. LPS from gram negative bacterial cell walls) or 
damage-associated molecular pattern molecules (DAMPs) (e.g. ECM cleavage 
products or molecules such as HMGB1 released from damaged cells). (Bianchi, 
2007). After binding TLR signaling pathways are activated leading to the secretion 
of pro-inflammatory cytokines. In vitro, Flii binds to the TLR adaptor protein 
MyD88 through its interaction with nucleoredoxin which inhibits MyD88 binding 
to TLR4 and reduces inflammatory cytokine secretion (Hayashi et al., 2010; T. 
Wang et al., 2006). Flii has also been localized to late endosome/lysosomes in 
fibroblasts and macrophages where it may also dampen inflammation (Lei et al., 
2012; Li et al., 2008). 
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Thus, the increased expression of Flii in human burn wounds and hypertrophic 
scars compared to normal skin is consistent with the hypothesis that Flii plays an 
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Despite the well-recognized burden of disease associated with hypertrophic 
scarring and considerable research in the area, we still have limited 
understanding of its pathogenesis. In particular, the cellular and molecular 
changes that drive fibroproliferation are poorly understood. As such, little 
progress has been made in developing new therapies to prevent or reduce 
hypertrophic scaring. 
 
Laboratory research into hypertrophic scarring can be divided into three broad 
categories: in vitro cell culture, which examines particular cell types under 
different conditions in order to elucidate their role in scarring; analysis of ex vivo 
human hypertrophic scar tissue via various techniques; and animal models of 
hypertrophic scarring. 
 
In vitro cell lines and primary cell culture have been useful in investigating the role 
of different cells and cytokines in hypertrophic scarring. However, this technique 
is limited by the considerable differences between in vitro conditions and the in 
vivo wound healing environment, where there are varied and complex 
interactions between many different cells, cytokines and extracellular matrix 
components. In addition, phenotype changes seen in cells cultured from 
hypertrophic scars have been found to no longer be present after initial passages 
(Larsson et al., 2008; Sargent & Whitfield, 2011). 





Analysis of ex vivo hypertrophic scar tissue excised from human patients can 
provide information on scar architecture, as well as the presence of different cell 
types and other constituents. Unfortunately, as discussed in Chapter 3, given the 
nature of scar surgery, these samples usually represent an end stage of the 
scarring process and provide little information about mechanisms preceding this. 
Similarly, tissue from burn surgery is either taken from an acute burn or a mature 
burn scar. This means that key events in hypertrophic scar development are 
rarely represented in human samples. Furthermore, the clinical classification of 
scar type or severity is highly arbitrary and variable from institution to institution 
(Lee et al., 2004). This further confounds any data gained from human tissue. 
 
Given the limitations inherent in techniques using in vitro and ex vivo human 
tissue, the need for an animal model of hypertrophic scarring is manifest. 
 
The development of an appropriate animal model has been problematic (Aarabi, 
et al., 2007), owing much to the phylogenetic variation in wound healing (Gurtner 
et al., 2008). For example, differences between mouse and human skin include 
denser hair covering with a shorter growth cycle than human hair; absence of 
dermal papillae/apocrine glands; and the presence of a full panniculus carnosus, 
which rapidly apposes wound edges after injury (Wong et al., 2011). There have 
been numerous attempts to develop an animal model of human hypertrophic 
scarring. Several models involve xenografts of human skin or hypertrophic scar 
onto immunodeficient mice (Escamez et al., 2004; Kischer et al., 1989) and rats 
(Polo et al., 1998). Although these models produced some of the histological 
changes seen in hypertrophic scars, they require significant suppression of the 





animals’ immune system, rendering any conclusions difficult to extrapolate to the 
human milieu. The Duroc pig displays similar scarring properties to the human 
(Goodwin et al., 1976; Zhu et al., 2003), but the experimental value of such a large 
animal model is limited by expense, housing and handling difficulties. A model 
utilising applied mechanical force (a well-recognised risk factor for hypertrophic 
scarring) across a murine incisional wound to stimulate fibroproliferation has 
been developed (Aarabi et al., 2007). Some models employ silicone splints to 
counter the effect of panniculus carnosus (Galiano et al., 2004). Despite these 
attempts, the need for a practical and reproducible animal model of hypertrophic 
scarring remains. 
 
The rationale behind our murine model is to recreate the pathological process 
underlying hypertrophic scarring by using bleomycin infusion to stimulate dermal 
fibroproliferation. Bleomycin is an antibiotic, originally isolated from 
Streptomyces verticillus and widely used as an anti-cancer treatment (Umezawa, 
1967). Bleomycin hydrolase inactivates bleomycin by hydrolysing the amide bond 
in the b-aminoalanineamide moiety. However, the shortage of this enzyme in the 
lungs and the skin, allows bleomycin-induced fibrosis and sclerosis to occur in 
these organs in a dose-dependent manner (Muggia, 1983). Bleomycin was first 
used to create animal models of pulmonary fibrosis, before Yamamoto and 
colleagues established a mouse model of scleroderma using daily subcutaneous 
injections over a 4-week period (Moseley et al., 1986; Yamamoto et al., 1999). 
 
We have adapted the dosage, delivery and temporal characteristics of this model 
to develop a novel model of hypertrophic scarring. Bleomycin is delivered 





continuously via a subcutaneous osmotic pump (Alzet Model 1004, Durect Corp., 
Cupertino CA 95014) in order to stimulate a fibrotic process rather than the 
dermal sclerosis described by Yamamoto et al. Bleomycin infusion provides a 
continuous inflammatory stimulus, in contrast to the daily dosing used in the 
scleroderma model. Mice were euthanized at 28-days or 56-days in an attempt to 
model both immature and mature hypertrophic scars. 








The osmotic pump and infusion was well tolerated by the mice (Figure 4.1). There 
were no obvious systemic differences in the bleomycin cohort compared to the 
control cohort. As the model did not involve a gross epidermal breach and the 
pump was positioned away from the insertion site (Figure 4.1), no macroscopic 
scarring was observed. The appearance of the murine skin was assessed for gross 
changes in appearance but none were observed between the treatment groups. 
 
4.2.1. The bleomycin model produces tissue 
architecture that corresponds to hypertrophic scars. 
 
To determine whether the lesions produced in response to bleomycin infusion 
reproduced the features of hypertrophic scar, normal mouse skin and sections 
from the 28-day and 56-day models were stained with haemotoxylin and eosin. 
These were examined under light microscopy and compared with similarly 
stained normal human skin and hypertrophic scar samples from the RAH Adult 
Burn Centre (Figure 4.1). 
 
No difference was observed between PBS infused control skin and untreated 
murine skin in terms of dermal thickening or skin architecture for the 28-day 
model or the 56-day model (Figure 4.1). 





The 28-day model lesions displayed marked dermal thickening, compared to the 
control samples. This was associated with a hyperplastic epidermis, increased 
cellularity and a reduction in the number of dermal appendages compared to 
control (Figure 4.1). The 56-day model lesions had increased dermal thickness 
compared to the 28-day model and control samples. They also displayed a 
flattened epidermis and an absence of dermal appendages, both features 







Fig. 4.1 The bleomycin model reproduces histologic architecture of 
hypertrophic scars. Control (PBS treated) murine skin, 28-day model lesion and 
56-day model lesion compared with normal human skin, immature hypertrophic 
scar and mature hypertrophic scar (above). The 28-day model displays dermal 
thickening, a paucity of dermal appendages and hyperplastic epidermis. These 
features are consistent with those displayed in an immature hypertrophic scar. 
The 56-day model displays a marked dermal thickening, absence of dermal 
appendages and a flattened epidermis. These features are consistent with those 
displayed in a mature hypertrophic scar. Scale bars = 100µm 
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Quantification of dermal thickness was performed using the Image Pro-Plus 5 
program. The 28-day model lesions displayed dermal thickening, which was 
significantly increased compared to control (202.5±30.93µm vs. 30±5µm, p < 
0.0005). 
 
The 56-day model lesions had significantly increased dermal thickness compared 
to both control samples and 28-day model samples (726.72±77.18µm vs. 30±5µm, 
p < 0.0005; 726.72±77.18µm vs. 202.5±30.93µm, p < 0.0005) (Figure 4.2). 
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Figure 4.2 Quantification of dermal thickness: Quantification of dermal 
thickness was performed using the Image Pro-Plus 5.1 program. The 28-day 
bleomycin model produced a dermal thick more than 6 times that of the control 
samples. The 56-day model produced a dermal thickness approximately 30 times 
that of the control samples, and 3 times that of the 28-day bleomycin model. 
***p<0.0005; error bars = SEM 
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4.2.2 The bleomycin model displays histopathological 
features of hypertrophic scars 
 
There are a number of classic histopathological features associated with 
hypertrophic scars including collagen nodules and whorls, thickened hyperplastic 
epidermis and abnormal dermal collagen organisation (J. Y. Lee et al., 2004). 
Samples of immature and mature human hypertrophic scars obtained from burn 
patients were stained with H&E, as well as lesions from the 28-day and 56-day 
models. These samples examined by light microscopy in order to determine 
whether histopathological features of human hypertrophic scars were 
reproduced in bleomycin-induced lesions. 
 
Collagen nodules and collagen whorls are features of hypertrophic scar and were 
present in lesions of both the 28-day model and the 56-day model, although they 
appeared to be most prevalent in the 28-day lesions (Figure 4.3). 
 
In both models, abnormal dermal collagen organisation was observed. Collagen 
arrangement was disorganised in the 28-day model, while the 56-day model 
displayed collagen arranged in sheets parallel to the surface of the skin. This 
corresponds to the collagen arrangement seen in immature and mature 
hypertrophic scars respectively (Figure 4.4). 
 
Epidermal layers of the 28-day and 56-day model lesions displayed basal disarray 
and vacuolar change. The epidermis of 28-day model lesions was hyperplastic and 





displayed rete pegs/dermal papillae, whereas the epidermis of the 56-day model 




Figure 4.3 The bleomycin model reproduces histopathological features of 
hypertrophic scars. Samples of immature hypertrophic scars; mature 
hypertrophic scars; and lesions from 28-day model and 56-day model were 
stained with H&E and photographed at 20x or 40x magnification. Mature 
hypertrophic scars demonstrated parallel sheets of collagen in the dermis, and 
similar collagen organisation was seen in the 56-model (arrowheads; far left). 
Immature hypertrophic scars demonstrated collagen nodules and whorls; similar 
nodules whorls were observed in the dermis of 28-day model lesions 
(arrowheads; middle left). Hyperplasia and basal cell disarray was seen in 
immature hypertrophic scars; similar epidermal changes were seen in the 28-day 
model lesions (arrowheads; middle right). Mature hypertrophic scars displayed a 
flattened epidermal layer with basal disarray and vacuolar change; similar 
epidermal changes were seen in 56 day-model lesions (arrowheads; right). Scale 
bars = 100µm 





4.2.3 Collagen content and composition of bleomycin 
induced lesions is analogous to hypertrophic scars 
 
Alterations in the amount of collagen and the ratio of collagen-1 to collagen-3 
(collagen-1:3) are associated with hypertrophic scarring (Zhang et al., 1995). 
Immunohistochemical localisation and quantification of collagen-1 and collagen- 
3 revealed a significant increase in the ratio of 28-day model lesions compared to 
normal murine skin (3.12±0.10 vs. 0.90±0.11, p < 0.0005). The collagen-1:3 ratio 
in the 56-day model was significantly lower than the 28-day model (0.72±0.12 vs. 
3.12±0.10, p < 0.0005). There was no significant difference between the 56-day 
ratio and the ratio of normal murine skin. (Figure 4.4) 

































Fig. 4.4 Lesions produced by the 28-day and 56 day bleomycin models have 
altered collagen-1:3 ratios. Samples from control skin, 28-day model lesions 
and 56-day model lesions were stained using Masson’s Trichrome and using 
immunohistochemistry for collagen-1 and collagen-3 (above). Collagen 
expression was then quantified using the AnalySIS software package and this data 
was used to calculate the collagen-1: collagen-3 sample for each lesion (below). 
Scale bars = 100µm; ***p<0.0005; error bars = SEM. 





4.2.4 Key determinants of fibroproliferation are 
increased in the bleomycin model. 
 
Normal mouse skin, 28-day lesions and 56-day lesions were co-stained with αSMA 
(α-smooth muscle actin) and DAPI (4',6-diamidino-2-phenylindole) to identify 
myofibroblasts. Myofibroblasts are the key cell type found in hypertrophic scars 
and express αSMA, which distinguishes them from fibroblasts and gives them 
their contractile properties. (Hinz, 2010). DAPI is a fluorescent stain that binds 
strongly to A-T rich regions in DNA and therefore is used in immunofluorescent 
staining to identify cell nuclei. 
 
Myofibroblasts were identified as αSMA-positive cells within the dermis of the 
samples and expressed as a percentage of total cells/high powered field 
(cells/HPF). There was a significant increase in the percentage of αSMA-positive 
cells/HPF in both the 28-day (87.67±2.30% vs. 18.19±3.05%, p<0.0005) and 56- 
day models (76.84±4.14% vs. 18.19±3.05%, p<0.0005) compared to normal skin. 
The reduction in the percentage of αSMA-positive cell/HPF in the 56-day model 
lesions compared to the 28-day model lesions was statistically significant 
(87.67±2.30% vs. 76.84±4.14%, p<0.05) (Fig. 4.5) 
 
TGF-β1 is the most investigated pro-inflammatory and pro-scarring cytokine in 
wound healing (Bayat et al., 2003). Normal mouse skin, 28-day lesions and 56-day 
lesions were stained using immunohistochemistry for TGF-β1. TGF-β1 was 
expressed in the epidermal layer of 28-day lesions and 56-day lesions as well as 





in cells throughout the dermis. These images then quantified using the AnalySIS 
software package. There was a significant increase in TGF-β1 expression in the 
epidermal layer of both 28-day model lesions (14.00±1.95 vs 3.00±0.91, 
p<0.0005) and the 56-day model lesions (18.00±2.34 vs. 3.00±0.91, p<0.0005). 
There was also a significant increase in dermal TGFβ1 in both the 28-day model 
lesions (9.11±1.74 vs. 1.72±0.18, p<0.0005) and the 56-day model lesions 
(3.62±0.50 vs 1.72±0.18, p<0.005). There was a statistically significant reduction 
in dermal TGF-β1 in the 56-day model lesions compared to the 28-day model 





Figure 4.5 Myofibroblasts are increased in the bleomycin model scars 
compared to control Normal mouse skin, 28-day lesions and 56-day lesions 
were co-stained using immunohistochemistry for αSMA and DAPI 
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Figure 4.5 (cont.) Myofibroblasts are increased in the bleomycin model scars 
compared to control images were then quantified using the AnalySIS software 
package in terms of cellularity per high power field (HPF) and the percentage of 
these cells positive for αSMA (right). Scale bars = 100µm; ***p<0.0005; 
**p<0.0005; *p<0.0005; error bars = SEM, n=6. 
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Figure 4.6 TGFβ1 is increased in bleomycin model scars compared with 
controls. Normal mouse skin, 28-day lesions and 56-day lesions were stained 
using immunohistochemistry for TGFβ1 (left). TGFβ1 was expressed in the 
epidermal layer of 28-day lesions and 56-day lesions and also in cells throughout 
the dermis. These images then quantified using the AnalySIS software package 
(right). Scale bars = 50µm; ***p<0.0005; **p<0.0005; *p<0.0005; error bars = SEM, 
n=6. 
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Most existing models of hypertrophic scaring have focused on reproducing the 
histopathological characteristics of the hypertrophic scar, rather than modeling 
the process that leads to its development (Ramos et al., 2008). Hypertrophic scars 
and keloids were originally defined by their clinical characteristics, before 
attempts were made to define them as distinct pathologies with distinct 
histological characteristics, such as parallel collagen fibres, collagen whorls and 
epidermal flattening (Lee et al., 2004). However, producing evidence to support 
these definitions has been difficult; indeed the histological distinction between 
normal scars, hypertrophic scars and keloid scars is controversial (Lee et al., 2004; 
Muyembe-Tamfum et al., 2009). There is currently no consensus in the literature 
regarding the relative contribution of different collagen subtypes to hypertrophic 
scar tissue fibrillogenesis, nor the importance or temporal profile of key cell types, 
such as myofibroblasts, or well-known cytokines, such as TGF-β1 (Dale et al., 
1996; Fleischmajer et al., 1990; Rawlins et al., 2006; Umezawa, 1967). 
 
It may be important to re-contextualise hypertrophic scarring as a 
fibroproliferative disease, sharing a common mechanism of fibrosis with systemic 
scleroderma, lung fibrosis or glomerulosclerosis, albeit it with a unique organ (the 
skin) and aetiology (Wynn, 2008). It follows that, instead of settling on the 
hypertrophic scar phenotype as an endpoint, an ideal animal model would be one 
that focuses on the fibroproliferation that characterises hypertrophic scarring and 
other fibrotic diseases. 
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Previous studies have used a daily injection of bleomycin into the skin of mice to 
induce scleroderma (Yamamoto et al., 1999). In these trials, bleomycin-treated 
dermis showed sclerosis with thickened, homogenous collagen bundles, 
perivascular infiltrates and thickening of the vascular wall. We adapted this 
method by delivering bleomycin via a subcutaneous osmotic pump, which 
delivered bleomycin at a constant rate of 0.11µL/hour for 28 days. This technique 
not only limited animal pain and distress but also provided a continuous 
inflammatory stimulus, in contrast to once daily doses (Yamamoto et al., 1999). 
Bleomycin has a relatively short half-life and has been demonstrated to exert a 
greater dose response when delivered as an infusion rather than individual doses 
(Sikic et al., 1978; Sikic et al., 1978) 
 
This model generated all the histopathological features that characterise human 
hypertrophic scarring, including dermal thickening due to collagen deposition, 
parallel collagen fibre orientation, collagen whorls, loss of dermal appendages and 
flattening of the epidermis. 
 
Immature and mature hypertrophic scars were obtained depending on the length 
of time that samples were taken post treatment with bleomycin. After 28 days of 
bleomycin infusion, murine skin exhibited a thickened epidermis and 
inflammatory cell infiltrate consistent with a developing or immature 
hypertrophic scar. However, at day 56, dermal thickness had continued to 
increase, and an absence of dermal appendages and a flattened epidermis were 
observed. This ongoing fibroproliferation occurred even though the bleomycin 
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infusion had ceased at day 28; this is consistent with Yamamoto’s results showing 
sustained phenotypic changes in fibroblasts after exposure to bleomycin 
(Takagawa et al., 2003). 
 
Changes in extracellular matrix composition and collagen fibrillogenesis are key 
features of fibrotic disease (Karsdal et al., 2013). It is known that the ratio of 
collagen-1:collagen-3 is altered compared in fibrotic diseases, including 
hypertrophic scarring, although, there is conflicting evidence as to the exact 
nature of this alteration due to most studies using heterogeneous groups of human 
samples and varying considerably in their methodology {Rawlins, 2006 #648}. 
The 28-day mouse model showed a significant increase in the ratio of collagen-1: 
collagen-3 compared to normal mouse skin. The 56-day model had a collagen-1: 
collagen-3 ratio that was not significantly different from normal skin. These 
changes may reflect the reorganization and remodeling of collagen subtypes 
similar to that occurring in normal wound healing (collagen-3 produced early in 
the proliferative phase of wound healing is replaced by collagen-1). Further 
investigation of collagen production and fibrillogenesis by more informative 
methods, such as electron microscopy, is required 
 
Bleomycin is known to induce production of reactive oxygen species and cause 
damage to endothelial and other cells types (Yamamoto & Nishioka, 2005a). In 
addition, bleomycin directly stimulates the pro-fibrotic TGF-β pathway, as well as 
a range of other pro-inflammatory and pro-fibrotic mediators such as chemo- 
attractant protein 1, PDGF, Il-4, Il-6 and Il-13 (Yamamoto & Nishioka, 2005a). In 
this way, bleomycin causes scarring by direct activation of inflammatory and 





fibrotic mediators that have been shown to be important to the development of 
human hypertrophic scarring. This process does not involve an epidermal injury, 
which is the first event in any human wound leading to hypertrophic scarring. The 
benefit of avoiding epidermal wounding in the mouse model is that it circumvents 
the need to deal with the confounding differences between murine and human 
wound healing. In mice, the panniculus carnosus causes early wound contraction, 
limiting the requirement for healing by secondary intention (Cameron et al., 
2013). By using bleomycin, we directly stimulate the fibroproliferative pathway 
common to every hypertrophic scar. 
 
It follows that one criticism of the bleomycin model is that it does not allow 
investigation of the role of restoring epidermal integrity in reducing hypertrophic 
scarring, which is known to be important in the reduction of hypertrophic scarring 
in burn injury (Cameron et al., 2013). This might be better investigated using a 
model designed specifically to measure re-epithelialisation (such as an excisional 
or burn wound). 
 
Any study using animals in order to model human disease should always 
acknowledge the significant differences between that animal and the human 
phenotype. Indeed a recent publication showed that genomic inflammatory 
responses in mouse models of human disease differed considerably from the 
genomic response seen in the corresponding human disease. In fact, the genes 
activated in the mouse model are close to random in matching the human disease 
genes. For this reason, murine models of human disease should always be viewed 





with some skepticism and only be considered in conjunction with in vivo and 
human data (Seok et al., 2013). 
 
A novel model of immature and mature hypertrophic scarring has been created, 
using the infusion of bleomycin to stimulate dermal fibroproliferation. This model 
reproduces morphological, histological and biochemical characteristics of human 
hypertrophic scars and presents two distinct windows in which to investigate scar 
formation and test potential anti-scarring therapies. For investigations directed 
at inflammatory response which drives fibroproliferation, the 28-day model 
would be most appropriate. For therapies designed to increase scar remodeling, 
the 56-day model would potentially be useful. 
 
The bleomycin model has considerable potential to be used to understand the 
complex processes involved in the formation of hypertrophic scars and allows for 
preclinical evaluation of anti-scarring therapies, whether they are directed at 
either the aberrant inflammatory response that leads to hypertrophic scarring or 
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Studies have shown that the protein Flightless I (Flii) is a regulator of the wound 
healing process (Adams et al., 2009; Cowin et al., 2007; Jackson et al., 2012). Flii 
is a member of the gelsolin family of actin-remodeling proteins that regulate actin 
by severing pre-existing filaments and/or capping filament ends to enable 
filament reassembly into new cytoskeletal structures (Kopecki et al., 2011). Flii 
co-localizes with molecules involved in regulating cytoskeletal reorganization, 
including members of the Rho family of GTPases, Ras and Cdc42 (Campbell et al., 
1993). It possesses a unique leucine-rich repeat domain, which is important for 
protein–protein interactions (Claudianos & Campbell, 1995). Cells within the 
epidermis and dermis express Flii and Cowin et al. have shown that Flii is able to 
translocate from the cytoplasm to the nucleus in response to wounding (Cowin et 
al., 2007). Focal adhesions and migratory structures involved in cellular motility 
also express Flii (Davy et al., 2000) and it is also secreted from cells. 
 
Flii has been investigated in a number of wound healing models of the past decade. 
In normal wound healing, In Flii+/- mice, wound healing under normal conditions 
is enhanced, whereas in FliiTg/Tg mice, healing is impaired, with delayed epithelial 
migration and increased scarring (Cowin et al., 2007). In vitro, Flii+/- fibroblasts 
and keratinocytes have improved cellular adhesion and spreading resulting in 
accelerated scratch wound closure (Cowin et al., 2007; Kopecki et al., 2009). 
Additionally, reducing Flii in a murine model of partial-thickness burn injury led 
to faster re-epithelialization and reduced scar formation (Adams et al., 2009) 





compared to wild type, suggesting the reduction of this protein in wounds may be 
beneficial as a treatment for hypertrophic scarring. Flii has also been shown to 
improve wound healing in models of impaired wound healing, namely murine 
models of diabetic wounds (Ruzehaji et al., 2013) and skin blistering/EB (Kopecki 
et al., 2013). 
 
These studies have identified Flii as a potential target for a novel therapy to 
improve wound healing. However, in many of these initial findings, Flii was 
reduced by virtue of a heterozygous Flii+/-. For this reason, a monoclonal antibody 
was developed as a topical or injectable therapy which inactivates Flii in the 
wound healing environment. This has been shown to improve wound healing in a 
similar manner to what has been seen in the heterozygous animals across the 
different models used (Jackson et al., 2012; Kopecki et al., 2013; Ruzehaji et al., 
2013). 
 
Interestingly, Flii, like other gelsolin proteins is secreted in response to tissue 
injury and is likely to be a mediator of inflammation (Lin et al., 2011). Secretion of 
gelsolin family proteins into the circulation has been linked to functions in 
scavenging actin (Bucki et al., 2008). The FnAb has been shown to deplete Flii in 
conditioned media by over 90% (Lei et al., 2012). Thus, FnAb appears to “mop-up’ 
this extracellular to bring about improved wound healing. Flii secretion has been 
characterized (Lei et al., 2012) but Flii cell surface receptors have not yet been 
identified. However, FnAb has been shown to be taken up into cells (Kopecki et al., 
2013) so it may have wound healing effects in both the extracellular and 
intracellular milieus. 
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Given the relationship between impaired wound healing and the development of 
hypertrophic scars, we have investigated whether Flii has a regulatory role in the 
fibroproliferative process that leads to hypertrophic scar formation. Here we 
examine the expression of Flii in human hypertrophic scars and investigate the 
effect of differential expression of Flii in a murine model of hypertrophic scarring 
as well as determining whether injection of a neutralizing antibody to Flii (FnAb) 
(Jackson et al., 2012) can reduce hypertrophic scar formation. Several 
determinants were used to measure scarring severity. Scar architecture was 
measured via dermal thickness and scar cross-sectional area. Collagen 
composition has also been shown to be linked to hypertrophic scarring severity, 
with an increased ration of collagen-1: collagen-3 indicating hypertrophic scarring 
(Hayakawa et al., 1982; Zhang et al., 1995). Myofibroblasts are differentiated 
fibroblasts involved in wound contraction and contribute to the development of 
hypertrophic scars. SMA is used as a marker of myofibroblasts and distinguishes 
them from undifferentiated dermal fibroblasts (Hinz et al., 2007). Collagen 
content and SMA positive cells were also measured to determine scarring 
severity. 
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5.2.1 Decreasing Flii reduces acute and mature scar 
formation 
 
After 4 weeks of bleomycin treatment, Flii+/- mice displayed significantly thinner 
dermis compared with WT (wild type) (145.4µm ± 5.7µm vs. 203.0µm ± 14.8µm, 
p < 0.05) and FliiTg/Tg (145.4µm ± 5.7µm vs. 344.7µm ± 16.9µm, p < 0.0005) in the 
developing/immature hypertrophic scars (Fig. 5.1, 5.2). Similarly, but to a much 
greater extent, FliiTg/Tg displayed significantly thicker dermis mice compared with 
WT (1120.9µm ± 140.8µm vs. 627.8µm ± 73.7µm, p < 0.05) and Flii+/-  (1120.9µm 
± 140 8µm vs. 726.7µm ± 128.9 µm, p < 0.05) at day 56 (Fig. 5.1). The 
developing/immature hypertrophic scar at day 28 showed that FliiTg/Tg mice had 
a significantly higher cross-sectional area compared with both Flii+/- (76 361.9µm2 
± 2895.6µm2 vs. 42 608 4µm2 ± 6784.3µm2, p < 0.0005) and WT (76 361.9  µm2 ± 
 
2895.6µm2 vs. 48 144.9µm2 ± 7135.2µm2, p < 0.005) (Fig. 5.3, 5.4). There was also 
a significantly higher cross-sectional area in the mature scars of the FliiTg/Tg mice 
compared with both WT and Flii+/- (106 454.8µm ± 21 838.1µm2 vs. 51 566.2 µm2 
± 3134.3 µm2: p  < 0.05; vs.  36 597.8µm2  ± 7564.3µm2,  p  < 0.0005)  at  day 56. A 
 
significant reduction in scar area in Flii+/- mice compared with WT was also 
observed (36 597.8µm2 ± 7564.3µm2 vs. 51 566.2µm2 ± 3134.3µm2, P < 0.05) at 
this later time. 
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Fig. 5.1 Decreasing Flii reduces dermal thickness in 28-day and 56-day 
fibrosis models. Representative haematoxylin and eosin images of dermal 
thickness of scars after 28 days and 56 days. Microscopic analysis showed a 
significant decrease in dermal thickness in Flii+/- scars at 28 days compared with 
WT and FliiTg/Tg. Original magnification x6. Scale bar = 50 µm2. 
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Figure 5.2 Decreasing Flii reduces dermal thickness in 28-day and 56-day 
fibrosis models. Graph showing changes in dermal thickness after 28 and 56 
days. There was a significant increase in dermal thickness in the FliiTg/Tg compared 
with WT and Flii+/- at 56 days. n = 6. Mean ±SEM. *p < 0.05, **p < 0.005, *** p < 
0.0005. 
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Figure 5.3 Decreasing Flii reduces scar cross sectional area in day-28 and 
day-56 fibrosis models. Representative stitched haemotoxylin and eosin images 
of total scar cross-sectional area at 28-days. Scale bar = 50 µm2 




















Figure 5.4 Decreasing Flii reduces scar cross sectional area in day-28 and 
day-56 fibrosis models. Microscopic analysis of images represented in Fig. 5.3 
showed that Flii+/- scars had significantly less cross sectional area at 56 days 
compared with WT and FliiTg/Tg, n=6. Mean ±SEM. *p < 0.05, **p < 0.005, *** p < 
0.0005. 





5.2.2 Reducing Flii reduces collagen-1:3 ratio 
 
More dermal collagen was observed in both 28-day and 56-day scars using 
Masson’s trichrome staining compared with controls. Collagen-1 expression was 
higher at day 28 and day 56 in FliiTg/Tg mice. Conversely collagen-3 was highest in 
the Flii+/- mice scars and lowest in the FliiTg/Tg mice (Fig. 5.5, 5.6). When formulated 
as a ratio, collagen-1:3 was significantly higher in FliiTg/Tg developing/immature 
scars compared with both WT (1.44±0.19 vs. 0.720±.15, p<0.005) and Flii+/- at 28 
days (1.44±0.19 vs. 0.57±0.13, p<0.0005). In 56-day mature scars, the collagen- 
1:3 ratio in FliiTg/Tg  scars was also significantly higher compared with WT 
(3.13±0.13 vs. 0.92±0.012, p < 0.0005) and Flii+/-  (2.60±0.38 vs. 0.92±0.012, 
p<0.0005). A lower collagen-1: collagen-3 ratio was observed in these mature 
scars at day 56 in FliiTg/Tg compared to WT but this was not statistically significant 
(Fig 5.5-5.6). 
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Fig. 5.5 Increasing Flii increases collagen-1:3 ratio in the 28-day model. 
(above) Representative Masson’s trichrome images and immunofluorescent 
images showing total collagen and collagen 1 and 3 distribution in day-28 scars. 
(below) Optical density analysis of immunofluorescent images shows a significant 
increase in the collagen-1:3 ratio in FliiTg/Tg compared with WT and Flii+/-. n = 
6. Mean SEM. *P < 0 05, **P < 0 005, ***P < 0 .0005.  
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Fig 5.6 Decreasing Flii reduces collagen-1:3 ratio in the 56-day model 
(above) Representative Masson’s trichrome images and immunofluorescent 
images showing total collagen and collagen-1 and 3 distribution in day-56 scars. 
(below) Optical density analysis of immunofluorescent images shows a 
significant decrease in the collagen-1:3 ratio in Flii+/- scars compared with WT 
and FliiTg/Tg scars. n = 6. Mean = SEM. *P < 0 05, **P < 0 005, 
***P < 0 .0005. 
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5.2.3 Manipulation of Flii level affects key determinants 
of scarring. 
 
The 28-day developing/immature scars in the Flii+/- mice had significantly less 
epidermal and dermal TGF-1 expression compared with WT (epidermal - 42±8.7 
vs. 145±4.3, p<0.05; dermal – 40.7±1.3 vs. 113±4.8, p<0.005) and FliiTg/Tg 
(epidermal - 42±8.7 vs. 264±10.1, p<0.005; dermal - 40.7±1.3 vs. 130±12.1) (Fig. 
5.7 a,c). Similarly, in the 56-day mature scars, Flii+/- mice displayed significantly 
less TGF-1 in both skin layers compared with WT (epidermal – 103.3±1.3 vs. 
246.3±4.8, p<0.005; dermal – 23.8±0.8 vs. 40.5±0.12, p<0.05) and FliiTg/Tg 
(epidermal - 103.3±1.3 vs. 348.8±17.6, p<0.0005; dermal - 23.8±0.8 vs. 127.5±9.8, 
p<0.0005). (Fig. 5.7 ). 
 
- SMA-positive cells within the dermis were expressed as a percentage of total 
cells per field of view. Significantly fewer myofibroblasts were observed in 28-day 
developing/immature scars in the Flii+/- mice compared with WT (61±4.3 cells vs. 
174.5±14.8 cells, p <0.005) and FliiTg/Tg (61±4.3 cells vs. 195.4±13.7cells, p < 
0.0005). Similarly, there were significantly fewer myofibroblasts in the mature 
scars of the Flii+/- mice compared with WT at 56 days (26.8±2.2 cells vs. 96±6.73 
cells, p<0.0005) and FliiTg/Tg (26.8±2.2 cells vs. 139.8±5.5 cells, p<0.0005). (Fig. 
5.8). There were also significantly fewer myofibroblasts in WT mature scars 
compared with FliiTg/Tg (96±6.73 cells vs. 139.8±5.5 cells, p <0.005). (Fig. 5.8). 
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Figure 5.7. TGF-1 expression is higher as Flii levels are increased (above) 
Representative immunofluorescent images showing TGF-1 expression 
throughout the epidermis and dermis of Flii+/-, WT and FliiTg/Tg scars. Optical 
density analysis shows a significant increase in TGF-1 as Flii levels increase 
across the genotypes at 28 days (below left) and 56 days (below right). Scale bar 
= 50 lm. n = 6. Mean SEM. *P < 0 05, **P < 0 005, ***P < 0 0005. 
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Figure 5.8 Decreasing Flii leads to a decrease in myofibroblasts  
Representative immunofluorescent images showing a-SMA and DAPI positive 
cells (above). Microscopic analysis showed significantly fewer myofibroblasts in 
Flii+/= scars compared with WT and FliiTg/Tg at 28 days (below left) and 56 days 
(below right). In the 56 day model increasing Flii in the FliiTg/Tg model led to a 
significantly increased number of fibroblast.  Scale bar = 50 lm. n = 6. Mean 
SEM. *P < 0 05, **P < 0 005, ***P < 0.0005 
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5.2.4 Flightless I neutralizing antibody treatment reduces fibrosis in day 28 
scars 
FnAbs have previously been shown to decrease the level of Flii in wounds and 
improve healing. To determine if FnAb could reduce the development of 
hypertrophic scars, bleomycin-induced fibrotic lesions were injected with FnAb 
or IgG (control) at days 0, 7, 14 and 21. Histological assessment of day 28 scars 
showed that FnAb-treated mice had significantly smaller scar areas compared 
with IgG-treated controls (39324.6 μm2 ± 5126.4 μm2 vs. 71115.9μm2 ± 4897.3, p 
< 0.05) (Fig. 5a, b) and dermal thickness 154μm ± 5.3μm vs. 209.7μm ± 31.7μm, p 
 
< 0.05). Furthermore, FnAb-treated scars also had significantly reduced collagen- 
1:3 ratios compared with IgG-treated controls (0.824 ± 0.31 vs. 2.92 ± 0.98, 
p<0.05). (Fig. 5.9 c, d). 
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Fig 5.9 FnAb treatment reduces scarring in the 28-day model of acute 
fibrosis. (a) Treatment with 20 g/m.  FnAb caused a significant reduction in 
both dermal thickness and scar cross-sectional area compared with IgG-treated 
controls. Scale bar = 50 lm. n = 3. (b) Graph showing changes in significant 
reduction in dermal thickness and cross-sectional area in the 28-day model of 
acute fibrosis compared with IgG-treated controls. Mean  SEM. *P < 0 05. 
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Fig 5.10 FnAb treatment reduces collagen-1:3 28-day model of acute 
fibrosis. FnAb-treated scars also show a significant reduction in the collagen-
1:3 ratio compared with IgG-treated controls. Scale bar = 50 lm. (b) Graph 
showing significant reduction in the collagen-1:3 ratio of FnAb-treated scars 
compared with IgG-treated controls. *P < 0 05. 










As shown in Chapter 3, Flii is upregulated in human burn wounds and 
hypertrophic scars compared with normal unwounded skin, suggesting a 
potential role for Flii in the regulation of the scarring process. However, given the 
heterogeneity of human samples, an animal model of hypertrophic scarring was 
required to investigate the role of Flii in more detail. Chapter 4 showed the 
development of an effective mouse model using bleomycin-induced fibrosis. This 
has been developed to induce developing and mature hypertrophic scarring, with 
histopathology that correlates well with human hypertrophic scars (Cameron et 
al., 2013). Bleomycin acts on fibroblasts, keratinocytes, endothelial and immune 
cells via TGF-1 and CTGF to drive fibroproliferative events (Yamamoto et al., 
2000). 
 
This chapter demonstrates that increasing the level of Flii (FliiTg/Tg mice) resulted 
in a significant increase in the severity of scar formation. Conversely, lowering Flii 
using a heterozygous knockout mouse (homozygous knockout being embryonic 
lethal) led to a reduction in scarring in terms of both dermal thickness and cross- 
sectional area. Additionally, when Flii levels were reduced using a neutralizing 
antibody (FnAb) administered in conjunction with the bleomycin treatment, a 
significant reduction in scar severity was observed, suggesting that decreasing the 
level of Flii could reduce the fibrosis observed with scar formation. 





TGF-1 is an important fibrogenic factor (Wynn, 2008). Reducing Flii expression 
has previously been reported to decrease TGF-1/ SMAD signalling, possibly 
through Flii forming a transcription complex with AP-1 proteins (Kopecki, Arkell, 
et al., 2011). In this study, scars of Flii+/- mice had decreased levels of fibrogenic 
TGF-1 compared with scars of both WT and FliiTg/Tg mice lesions, suggesting that 
Flii may potentially assist in reducing scarring severity via an effect on TGF-1. 
Myofibroblasts have also been implicated in the process of hypertrophic scarring 
and the detection of myofibroblasts and TGF-1 is highly significant for 
determining the degree of fibrosis (Hinz, 2010). In addition to producing the 
collagenous ECM comprising the hypertrophic scar, myofibroblasts can also 
promote fibrosis by secreting angiogenic, pro-inflammatory and fibrogenic factors 
(Darby et al., 2007). Scars in Flii+/- mice had significantly fewer myofibroblasts in 
the healing environment, suggesting that the anti-scarring effects of Flii may be 
mediated by an effect on myofibroblast differentiation, migration or survival. 
 
The collagen-1:3 ratio has been identified as an important factor in determining 
severity of scar formation (Dale et al., 1996). Collagen-3 is a member of the fibrillar 
collagen family and is colocalised with collagen-1 in the skin. Collagen-3 is 
essential for normal collagen-1 fibrillogenesis by regulating the diameter of the 
collagen-1 fibril (Liu et al., 1997). An increased collagen-1:3 ratio is associated 
with hypertrophic scarring (Hayakawa et al., 1982). In keeping with the 
improvement in scar thickness and area as seen in Flii+/- mice, Flii+/- scars had 
significantly reduced collagen-1:3 ratios compared with WT and FliiTg/Tg scars. 
Similarly, day 28 model mice treated with FnAb had significantly lower collagen- 
1:3 ratios compared with IgG-treated controls. 








This chapter demonstrates that Flii is a key regulator of the fibroproliferative 
process underpinning hypertrophic scarring. Reducing Flii in a bleomycin model 
of hypertrophic scarring, either genetically via gene knockdown, or via treatment 
with FnAbs, leads to significant improvements in scarring. Reducing Flii also led 
to a reduction in key determinants of scarring including TGF-1 and myofibroblast 
numbers. This study therefore identifies Flii as a potential therapeutic target for a 











EFFECT OF FLIGHTLESS ON 
FIBROBLAST PHENOTYPE IN VITRO 







To examine possible cellular mechanisms for the reduction in scarring seen in the 
bleomycin model, we investigated a putative role for Flii in the regulation of 
myofibroblast function and the fibroblast-myofibroblast transition. 
 
In skin, myofibroblasts arise from various precursor cells that differ according to 
the characteristics of injury(Hinz et al., 2012) and cytokines and express -SMA 
and the fibronectin (FN) splice variant ectodomain (ED)-A FNfibre (Hinz, 2010). 
The myofibroblast receives constant feedback from the extracellular matrix 
(ECM), which regulates its role in the wound healing process. This information 
then leads to responses in cell properties such as migration, proliferation, 
survival, differentiation, ECM organization and remodeling (Vogel & Sheetz, 
2006). The dysregulation of this process is the hallmark of fibroproliferative 
disease, which in the skin is characterized as hypertrophic scarring. 
 
Flii has a number of potential roles in the regulation of fibroblast-myofibroblast 
function. As an actin remodeling protein, Flii is important in the regulation of the 
actin cytoskeleton and consequently the motility, contraction and adhesion of 
cells (Davy et al., 2000). Flii has also been shown to act by inhibiting actin 
polymerization by capping, but not severing actin filaments (Mohammad et al., 
2012). When Flii is reduced, increased actin and focal adhesion turnover results 
and leads to increased cell motility. Flii modulates focal adhesions and filamentous 
actin stress fibres in a Rac-1 dependent manner (Kopecki, O'Neill, et al., 2011). Flii 
co-precipitates with focal adhesion proteins talin, paxillin and vinculin (Kopecki 





et al., 2009). In vivo, elevated Flii leads to increased stress fibre formation by 
impaired focal adhesion turnover and enhanced formation of fibrillar adhesions. 
Conversely, Flii knockdown increases the percentage of focal complex positive 
cells (Kopecki, O'Neill, et al., 2011). Flii knockdown cells exhibit lower levels of 
activated β1-integrin and vinculin, without any change in talin levels. This 
suggests that Flii may promote the recruitment of focal adhesion proteins like 
vinculin, which through its interaction affects β1-integrin activation (Mohammad 
et al., 2012). It is known that focal adhesions allow contractile activity of 
myofibroblasts to be transmitted to the ECM (Hinz et al., 2012), creating a more 
strained, stiffer environment. These mechanical conditions generated by the 
myofibroblast also lead to their sustained fibroproliferative activity (Hinz et al., 
2001). Indeed, scar development in a murine model of hypertrophic was 
prevented by disruption of Focal Adhesion Kinase (FAK) signalling pathway 
(Wong et al., 2012). Reducing Flii may potentially alter cell focal adhesions and 
prevent this sustained myofibroblast activation. 
 
It has recently been shown that specifically blocking TGF-1 mediated 
differentiation of myofibroblasts by preventing v integrin activation of latent 
TGF- prevents fibroproliferation in murine models of liver and lung fibrosis 
(Smith & Henderson, 2016). Flii may act in a similar manner to regulate 
myofibroblast function in fibroproliferation. 
 
Thus, this chapter investigates the effective of Flii on fibroblast function, 
specifically in regulating the fibroblast-myofibroblast transition associated with 
hypertrophic scarring. 







6.2.1 Flii is increased in human hypertrophic scar 
fibroblasts compared to human foreskin fibroblast 
 
Hypertrophic scar fibroblasts (HTSF) and human foreskin fibroblasts (HFFs) were 
cultured and subjected to immunocytochemistry for Flii as detailed in Chapter 2. 
There was a marked increase of Flii in HTSFs compared to HFFs. This was 
localized to the nucleus of the cells compared to the cytosolic distribution seen in 
HFFs. Morphological differences were also observed - with HTSFs appearing more 
spindle shaped compared with HFFs (Figure 6.1). 













Fig 6.1 Immunolocalisation of Flii in human foreskin fibroblasts (HFF) and 
hypertrophic scar fibroblasts (HTSF). Flii upregulated in HTSF and was 
localized to the nucleus of the cell. Scale bar = 50m. 





6.2.2 FnAb reduces fibroblast-myofibroblast phenotype 
change in HFFs co-cultured with bleomycin 
 
 
It has previously been shown that culturing fibroblasts in the presence of 
bleomycin induces a fibrotic fibroblast phenotype (Yamamoto, Eckes, et al., 2000). 
 
A bleomycin concentration of 140μg/ml was used based on concentrations used 
in Yamamoto’s work. A WST-1 assay was used to confirm that this dose did not 
cause significant cell toxicity (Appendix 1). Cellular lysates were collected and 
Western Blot Protein analysis was performed to determine relative levels of Flii 
and αSMA, with β-tubulin used to normalise protein levels. Levels of Flii protein 
and αSMA were increased in HFFs cultured with bleomycin compared to control 
and the addition of FnAb led to a reduction in Flii and αSMA levels, although not 
to control levels (Fig 6.2 (c)). 
 
 
Immunocytochemistry was then performed to correlate these findings. 
Bleomycin treated cells showed increased Flii expression, in a nuclear/peri- 
nuclear distribution, as well as increased expression of αSMA. Bleomcyin treated 
cells also appeared to have a more spindle like phenotype compared to control. 
Treatment with FnAb led to a reduction in Flii and αSMA expression and less 
pronounced spindle phenotype (6.2 (a)). 
 
It is known that myofibroblasts are less motile than their fibroblast counterparts 
(Ronnov-Jessen & Petersen, 1996). Scratch migration assays were therefore 
performed to determine whether FnAb treatment has an effect on cell motility. 





Confluent monolayers of HFF grown in 24 well plates were scratch wounded and 
cultured in the presence or absence of 140μg/ml bleomycin with 20μg/ml FnAb 
or 20μg/ml irrelevant murine IgG (control). Residual wound area was examined 
over 96 hours. HFFs cultured with bleomycin had significantly reduced motility 
compared with control HFFs. However, when treated with FnAb this motility was 
significantly increased. Addition of FnAb to control HFFs also resulted in a small 
but significant increase in motility (Fig. 6.2 (b)). 















Fig 6.2 Treatment of HFFs with bleomycin induces myofibroblast like 
phenotype changes that can be reduced by FnAb. (a) Immunocytochemistry 
for Flii in HFFs, HFFs treated with bleomycin and HFFs treated with bleomycin 
and FnAb. Treatment with bleomycin led to an increase in Flii and SMA. 
Addition of FnAb caused a reduction of Flii and SMA, although not to control 
levels. (b) Western blot of cellular lysates of HFF, HFF treated with bleomycin 
and HFF treated with bleomycin and FnAb. Treatment with bleomycin led to an 
increase in Flii and SMA, which was reduced after addition of FnAb. (c) Scratch 
assay showing decrease in motility of bleomycin treated HFFs compared with 
control HFFs. This decrease in motility is lessened by addition of FnAb. 







6.2.3 Treatment of primary fibroblasts from Flii+/-, WT 
and FliiTg/Tg mice with bleomycin and FnAb 
 
Immunocytochemistry for Flii and αSMA was performed on primary fibroblasts 
cultured from Flii+/-, WT and FliiTg/Tg mice. As expected, there was increased Flii 
expression in WT fibroblasts compared to Flii+/- and in FliiTg/Tg compared to WT 
and Flii+/-(Figure 6.3). Flii was upregulated in all three genotypes when cells were 
cultured with 140μg/ml bleomycin (Figure 6.3). Treatment with FnAb had little 
effect on Flii expression as detected by immunocytochemistry (Figure 6.3). αSMA 
was upregulated in WT fibroblasts compared to Flii+/- and in FliiTg/Tg compared to 
WT and Flii+/- (Figure 6.4). This trend was enhanced by culture with bleomycin. 
Treatment with FnAb reduced αSMA expression in both control and bleomycin 
groups across all genotypes (Figure 6.4). 










Figure 6.3 Treatment of primary fibroblasts from Flii+/-, WT and FliiTg/Tg 
mice with bleomycin and FnAb. Flii expression in three genotypes is increased 
after co-culture with bleomycin. There was no significant decrease of Flii 
expression in any genotype following addition of FnAb. 






















Figure 6.4 Treatment of primary fibroblasts from Flii+/-, WT and FliiTg/Tg 
mice with bleomycin and FnAb. SMA expression in three genotypes is 
increased after addition of bleomycin. This increase in expression is reduced by 
co-culture with FnAb. Main images x20 magnification, inset images x 50 
magnification of a single cell from main image. 






Scratch migration assay was used to assess the motility of the primary fibroblasts. 
As shown in our previous work (Cowin et al., 2007), Flii+/- displayed increased 
motility compared to WT, while motility of FliiTg/Tg compared to control was 
reduced. Culture with 140μg/ml bleomycin led to a significant decrease in 
motility of all genotypes compared to control. (Fig 6.5 (a)). Culture with 20μg/ml 
FnAb led to a significant increase in motility in FliiTg/Tg fibroblasts across all time 
points and a significant increase in motility of WT fibroblasts from 0-12 hours. 
There was no significant increase in motility of Flii+/- fibroblasts with addition of 
FnAb (Fig. 6.5 (b)). No differences were observed when cells were cultured with 
murine irrelevant IgG (control). 
 
Flii+/-, WT and FliiTg/Tg fibroblasts were then cultured with 140μg/ml bleomycin 
and treated with either 20μg/ml FnAb or control (20μg/ml murine irrelevant IgG). 
In all genotypes, the addition of FnAb increased the motility of bleomycin treated 
fibroblasts significantly. This treatment effect was most pronounced in FliiTg/Tg 
and WT, with a smaller but still significant effect observed in WT fibroblasts (Fig 
6.6 (a-c)). 







Figure 6.5 Effects of bleomycin and FnAb on motility of cultured primary 
Flii+/-, WT and FliiTg/Tg fibroblasts. (a) Treatment with bleomycin decreases the 
motility of Flii+/-, WT and FliiTg/Tg fibroblasts compared to control. (b) Addition of 
FnAb to primary fibroblast culture led to a significant increase in the motility of 
WT and FliiTg/Tg/- but not Flii+/-. 


















Figure 6.6 FnAb mediates the decreases in motility caused by treatment with 
bleomycin. In all genotypes, the addition of FnAb increased the motility of 
bleomycin treated fibroblasts significantly. This treatment effect was most 
pronounced in FliiTg/Tg and WT, with a smaller but still significant effect observed 
in WT fibroblasts. (a) Flii+/- (b) WT (c) Flii Tg/Tg 
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Myofibroblasts are key cells involved in hypertrophic scarring (Junker et al., 
2008). In addition to producing the collagenous extracellular matrix comprising 
the hypertrophic scar, myofibroblasts can also promote fibrosis by secreting 
angiogenic, pro-inflammatory and fibrogenic factors (Badid et al., 2000; Darby, 
2007). Chapter 5 showed that scars in Flii+/- mice had significantly fewer 
myofibroblasts in the healing environment, suggesting that the anti-scarring 
effects of Flii may be mediated by an effect on myofibroblast differentiation, 
migration or survival. Given the importance of the fibroblast/myofibroblast to the 
scarring process, it was pertinent to focus our in vitro studies on the effect of Flii 
on these cells. 
 
In keeping with this, the first section of this chapter shows that Flii expression is 
increased in fibroblasts cultured from human hypertrophic scars compared to 
human foreskin fibroblasts (Fig. 6.1). 
 
In keeping with the animal model used in this thesis, bleomycin was then used to 
induce a myofibroblast phenotype, as previously described (Yamamoto et al., 
2000). Fibroblasts cultured with bleomycin showed increased expression of 
αSMA, as well as decreased motility, characteristics of myofibroblasts. These cells 
also showed an increased expression of Flii and these changes could be partly 
prevented by treatment with FnAb (Fig. 6.2) 
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These trends were also evident when fibroblasts from Flii+/-, WT and FliiTg/Tg were 
cultured with bleomycin. Bleomycin treated cells showed increased Flii 
expression, increased αSMA and decreased motility. Treatment FnAb led to 
reduced αSMA and partially restored the migratory capacity observed in control 
groups. In future studies, image analysis and Western Blot protein analysis could 
be used to quantify immunohistochemical findings shown here, although time 
constraints did not permit this for this study. 
 
There are a number of putative mechanisms via which Flii may modulate 
fibroblast-myofibroblast behavior. Actin dynamics are integral to the wound 
healing process. After wounding cells respond to a variety of stimuli to remodel 
their actin cytoskeleton, which brings about changes in cell contraction, adhesion, 
motility or phenotype. Ras proteins are involved in the regulation of the actin 
cytoskeleton where their interaction with Raf-1 connects it to the mitogen- 
activated protein kinase (MAPK) pathway (Goshima et al., 1999). 
 
 
Flii can be induced by serum to translocate from the nucleus to leading edge of 
the cell, membrane ruffles and actin arcs where Flii colocalizes with Ras and 
GTPases (Davy et al., 2001).The co-localization of Flii with Ras is consistent 
with findings using kinetic analysis based on competitive inhibition of Ras- 
dependent adenylyl cyclase activity in which the results showed the 
association of the LRR domain of Flii with Ras (Davy et al., 2000; Goshima et 
al., 1999). Therefore, the interaction of Flii with Ras proteins provided a link to 
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the MAPK pathway. The connection of Flii to a signaling pathway is also 
supported by the interaction of Flii with the phosphoinositol-signaling 
pathway in the regulatory events during ovulation (Campbell, 1993) 
 
 
There is also evidence to suggest that Flii may actually be secreted by fibroblasts 
and so may act in a similar manner to the secretory phenotype of gelsolin that 
scavenges extracellular actin following tissue injury. 
 
The interaction between the actin cytoskeleton and the ECM occurs through 
highly dynamic, temporary adhesions known as focal complexes. These adhesions 
are formed by actin polymerization underneath lamellipodia. These have been 
described as a “molecular clutch” which connects the cytoskeleton to the matrix, 
thereby allowing actin-myosin generated tension to bring about cell traction (Le 
Clainche & Carlier, 2008). Focal complex function is a complex process 
determined by interaction between integrin-ECM, integrin-actin binding proteins 
and actin filament-actin binding protein interactions. In this way, focal complexes 
link the ECM to the actin cytoskeleton, essentially functioning as mechanosensors 
which can then influence maturation of adhesion sites and the recruitment of 
signaling or structural molecules (Lambrechts et al., 2004; Le Clainche & Carlier, 
2008). Under certain conditions focal complexes become larger, more stable 
adhesions known as focal adhesions, which are associated with stress fibre 
development and fibroblast transformation to myofibroblasts (Hinz, 2010). 
 
More recent work has shown that Flii modulates these focal adhesions and 
filamentous actin stress fibres in a Rac-1 dependent manner (Kopecki et al., 2011). 





Flii co-precipitates with focal adhesion proteins talin, paxillin and vinculin 
(Kopecki et al., 2009). In vivo, elevated Flii leads to increased stress fibre 
formation by impaired focal adhesion turnover and enhanced formation of 
fibrillar adhesions. Conversely, Flii knockdown increases the percentage of focal 
complex positive cells (Kopecki et al., 2011). Flii knockdown cells exhibit lower 
levels of activated β1-integrin and vinculin, without any change in talin levels. 
This suggests that Flii may promote the recruitment of focal adhesion proteins like 
vinculin, which through its interaction affects β1-integrin activation (Mohammad 
et al., 2012). It is known that focal adhesions allow contractile activity of 
myofibroblasts to be transmitted to the ECM (Hinz et al., 2012), creating a more 
strained, and stiffer environment. These mechanical conditions generated by the 
myofibroblast also lead to their sustained fibroproliferative activity (Hinz et al., 
2001). Reducing Flii may potentially alter cell focal adhesions and prevent this 











GENERAL DISCUSSION AND FUTURE 
DIRECTIONS 







Hypertrophic scarring represents an area of unmet clinical need. Occurring in 
more than 70% of deep burns, as well as after surgery or trauma it carries a 
considerable burden of disease including disfigurement, pain, disability and 
psychological co-morbidity (Brown et al., 2008). 
 
Current therapies focus mainly on managing hypertrophic scars once they have 
developed. These interventions are limited in their efficacy and the majority lack 
strong evidence for their efficacy (Mustoe et al., 2002). 
 
Improving our knowledge of the pathophysiology of hypertrophic scarring will 
contribute to a better understanding of the complex regulation of wound healing. 
This will potentially inform novel therapies to prevent or mitigate hypertrophic 
scarring. The work in this thesis focused on understanding the role of Flightless 
(Flii) in the fibroproliferative process that underlies hypertrophic scarring. 
 
 
7.2 A role for Flightless in 
hypertrophic scarring and the 
development of a novel murine model 
of hypertrophic scarring 
The human homologue of the Flii gene was identified by Campbell in 1997 
(Campbell et al., 1997) and was initially investigated in relation to embryogenesis 
and its role as a hormone-activated nuclear receptor co-activator (Campbell et al., 





2002; Davy et al., 2000). In 2007, our laboratory demonstrated that Flii deficient 
mice had improved wound healing, with increased epithelial migration and 
improved cellular proliferation, whereas Flii over expressing mice had impaired 
wound healing (Cowin et al., 2007). Since that time, we have shown that Flii is a 
key regulator of the wound healing process, in vitro and in vivo studies of normal 
wound healing, burn injury, diabetic wound healing and skin blistering disease 
(Kopecki et al., 2009; Kopecki et al., 2011; Kopecki et al., 2013; Kopecki et al., 2013; 
Ruzehaji et al., 2013). This study marks the first time that Flii has been 
investigated in the fibroproliferative process that underlies hypertrophic scarring. 
 
Chapter 3 showed, for the first time, that Flii is overexpressed in acute human 
burns and hypertrophic scars, suggesting a role for Flii in the pathogenesis of 
hypertrophic scarring (Cameron et al., 2016). Analysis of Flii expression in human 
samples comes with the caveat that these samples provide limited windows into 
the process of hypertrophic scar formation. In general, clinical practice dictates 
that only acute burns wounds (<14 days old) or mature hypertrophic scar are 
excised. Thus, little human tissue is available from the proliferative phase of 
wound healing, which is when the fibroproliferative process underlying 
hypertrophic scarring will be at its peak. Indeed, mature hypertrophic scars will 
have few cells at all in their dermis, tissue from acute burns wounds is usually so 
damaged that little architecture is preserved. 
 
Furthermore, what actually qualifies as a hypertrophic scar is unclear and 
problematic for research using human samples. Hypertrophic scars were 
originally described by clinical characteristics (red, raised, painful scars prone to 





contracture) (Herndon, 2012). Attempts were subsequently made to delineate a 
histological classification, via features such as parallel collagen fibres, collagen 
whorls and epidermal flattening (Lee et al., 2004). However, defining reliable 
histological characteristics to differentiate between normal scars, hypertrophic 
scars and keloid scars has proved difficult (Lee et al., 2004; Verhaegen et al., 2009). 
There is no consensus in the literature regarding the relative contribution of 
different collagen subtypes to hypertrophic scar fibrillogenesis, nor the 
importance or temporal profile of key cell types, such as myofibroblasts, or 
cytokines, such as TFG-1 (Rawlins et al., 2006). 
 
This confusion has hampered the development of an adequate animal model of 
hypertrophic scarring, with many models overly focused on reproducing the 
pathological endpoint of the process rather than modelling the process leading to 
this. By shifting focus from the pathological endpoint to the process by which this 
arises, hypertrophic scarring may be re-contextualised as a fibroproliferative 
disease, sharing a common mechanism with systemic scleroderma, lung fibrosis 
or glomerulosclerosis. This tenet provided the basis for the development of a 
novel model of hypertrophic scarring described in Chapter 4. Bleomycin had 
previously been used to model the fibroproliferation seen in lung fibrosis and 
scleroderma (Moseley et al., 1986; Yamamoto et al., 1999). By adapting the dosage, 
delivery and temporal characteristics of these models a novel model of the process 
of hypertrophic scarring was developed. This was based in the process of dermal 
fibroproliferation that underlies hypertrophic scarring, while also reproducing 
the morphological, histological and biochemical characteristics of human 
hypertrophic scars. Two time points (28 and 56 days) were chosen at which to 





analyse the scars, in order to ensure the inflammatory and maturation phases of 
the wound healing process were captured. 
 
The bleomycin model does not involve a breach of the epidermis. Rather an 
osmotic pump is placed in a subdermal pocket and bleomycin is leeched out to 
exert a direct effect on the murine dermis. A model of wound healing lacking an 
epidermal breach may appear controversial. Upon closer examination there are a 
number of reasons why this may be considered a strength. Foremost, there are 
already major differences between the anatomy and physiology of murine 
compared to human skin. Murine skin has denser hair with a shorter growth cycle 
than human hair while lacking dermal papillae and apocrine glands. Importantly 
the presence of the panniculus carnosus muscle layer, which is vestigial absent in 
humans, rapidly apposes murine wound edges after injury (Wong et al., 2011). 
The bleomycin model effectively excludes these potentially confounding 
mechanical and architectural differences and specifically targets dermal 
fibroproliferation. Indeed, during hypertrophic scarring dermal fibroproliferation 
is occurring long after the epidermis has healed(Cameron et al., 2010). The role of 
restoring epithelial integrity is undoubtedly of much interest in understanding the 
development of hypertrophic scarring; however, this would be best investigated 
using an alternative model. 
 
Some may also question the validity of using bleomycin, a toxic substance, in our 
model. Bleomycin directly stimulates the pro-fibrotic TGF- pathway, as well as 
other pro-inflammatory and pro-fibrotic mediators such as chemo-attractant 
protein 1, PDGF, Il-4, Il-6 and Il-13 (Yamamoto & Nishioka, 2005b). Bleomycin 





thus causes scarring by direct activation of inflammatory and fibrotic mediators 
that have been shown to be important to the development of human hypertrophic 
scarring. 
 
Any study employing animal models of human disease should always 
acknowledge the significant differences between that animal and the human 
phenotype. Indeed, recent evidence shows that genomic inflammatory responses 
in mouse models differ considerably from the genomic response seen in the 
corresponding human disease (Seok et al. 2013). In fact, the genes activated in the 
mouse model are close to random in matching the human disease genes. For this 
reason, murine models of human disease should always be viewed with some 
skepticism and only be considered in conjunction with in vivo and human data 
 
7.3 Potential mechanisms for the role 
of Flii in hypertrophic scarring 
 
7.3.1 TGF--Smad pathway 
Chapter 5 demonstrated that an increased level of Flii in FliiTg/Tg led to a 
significant increase in scarring in the murine model, while a reduced level of Flii 
in Flii+/- led to a significant decrease. This findings were also associated with 
increased and decreased levels of TGF-1 respectively, suggesting that this effect 
may Flii may exert an effect on scarring via TGF-1. 





The TGF- superfamily has been extensively investigated in relation to wound 
healing and scar formation (Wynn, 2008). The TGF--Smad signalling pathway is 
a central mediator in fibrogenic events such as chemotaxis, extracellular matrix 
synthesis and autocrine activation of growth factors (Pannu et al., 2007; Wilkes et 
al., 2005). TGF- is integral to the ontogenetic shift from scarless foetal healing to 
adult scar forming wound healing in the third trimester (Chen et al., 2005). TGF- 
signalling in fibroblasts has been shown to be important for production of 
extracellular matrix components, as well as regulating keratinocyte and the 
fibroblast to myofibroblast transition (Ong et al., 2009). 
 
Flii has been shown to be a modulator of TGF/Smad signalling, while studies by 
the Cowin team have shown that Flii affects wound healing through modulation of 
TGF-1 and TGF-3 expression in vivo (Adams et al., 2009; Adams et al., 2008) 
(Figure 7.1). Reducing Flii gene expression via siRNA in in vivo wounds or in vitro 
fibroblasts reduced TGF-1 levels while Flii overexpression led to upregulation of 
TGF-1. Lim demonstrated that Flii functions as a coactivator in the expression of 
the type I collagen gene COL1A2 induced by TGF- in cultured epithelial cells (Lim 
& Jeong, 2014). This suggested that Flii is required for TGF- induced chromatin 
remodelling carried out by the SWI/SNF complex. TGF- may also be involved in 
Flii interaction with extracellular matrix proteins, with Kopecki demonstrating 
that addition of TGF- reduces the Flii association with Collagen VII (Kopecki et 
al., 2011). Thus, there are several possible mechanisms by which Flii could 
regulate wound healing through the TGF--Smad pathway. In this study, TGF-1 





was seen to be decreased concomitant with improved scarring across both the 28- 
day and 56-day model. 
 
It has recently been shown that specifically blocking TGF-1 mediated 
differentiation of myofibroblasts by preventing v integrin activation of latent 
TGF- prevents fibroproliferation in murine models of liver and lung fibrosis 
(Smith & Henderson, 2016). Blocking Flii may act in a similar manner via the 
TGF- pathway to regulate myofibroblast function and reduce scarring. 
 
Interestingly, Flii, like other gelsolin proteins is secreted in response to tissue 
injury and is likely to be a mediator of inflammation (Lin et al., 2011). Secretion of 
gelsolin family proteins into the circulation has been linked to functions in 
scavenging actin (Bucki et al., 2008) The FnAb has been shown to deplete Flii in 
conditioned media by over 90% (Lei et al., 2012). Thus, FnAb appears to “mop-up’ 
this extracellular to bring about improved wound healing. Flii secretion has been 
characterized (Lei et al., 2012) but Flii cell surface receptors have not yet been 
identified. However, FnAb has been shown to be taken up into cells (Kopecki et al., 
2013) so it may have wound healing effects in both the extracellular and 
intracellular milieus. 

































Figure 7.1. Schematic illustrating potential sites of Flii interaction with 
TGF-Smad pathway 
 
7.3.2 Flii and other cell signaling pathways 
 
Numerous pathways involved in wound healing evens such as cytoskeletal 
remodeling, cellular adhesion and migration have been identified including TGF- 
. MAP kinase family, Ras, RhoA, MAPK-ERK kinase and ERK1/2 (Begum et al., 
2004; Bhowmick et al., 2001; Hall & Nobes, 2000; Wang et al., 2005). Flii has both 
cytoskeletal and nuclear regulatory functions, and has been shown to co-localise 
with different molecules involved in the aforementioned pathways, such as Ras 
and Cdc42 (Campbell et al., 2002; Lee & Stallcup, 2006). The ability of Flii to bind 
both Ras and Cdc42 suggests it may be involved in both PI3K and MAPK signaling 
pathways. Kopecki demonstrated an effect of Flii on modulation of small GTPases, 
including  Rac1,  RhoA  and  Cdc42  suggesting  that  Flii  could  be  involved  in 





mediating various signaling pathways through such interactions (Kopecki, O'Neill, 
et al., 2011). The effect of Flii on these pathways presents further possible 
mechanisms by which Flii may cause the effects on fibroproliferation 
demonstrated in this thesis. 
 
7.3.3 Flii regulation of keratinocyte function 
 
Immunohistochemistry of human burn samples in chapter 3 showed that Flii was 
seen predominately in the epidermis. This was also evident in murine model scars 
in Chapters 4 and 5, although significant dermal expression was shown 
presumably due to these scars being more representative of the inflammatory 
stage of wound healing. Clinicians have long understood the epidermis to be a key 
regulator of the wound healing process, with wounds that are slow to achieve 
epithelial coverage being more likely to undergo hypertrophic scarring (Herndon, 
2012). In keeping with this, keratinocytes have been shown to regulate 
fibroblasts, the key cell in hypertrophic scarring, through secretion, activation and 
inhibition of growth factors such as TFG- (Santoro & Gaudino, 2005). As our 
previous work has shown Flii’s role in keratinocyte migration after wound repair 
(Cowin et al., 2007), regulation of TGF- in burn wound healing (Adams et al., 
2009) and key role in epithelial integrity (Kopecki et al., 2009) there is a potential 
role for Flii in this epidermal regulation of mesenchymal activity. 





7.3.4 Flii and cytoskeletal regulation of the fibroblast 
 
Migrating cells undergo a series of structural changes involving protrusions of the 
leading edge of the cell, adhesion of this leading edge to substrate then freeing of 
adhesions at the trailing edge before forward movement of the body of the cell 
(Lauffenburger & Horwitz, 1996). When cell adhesion forces are low, cells cannot 
generate forces necessary for forward movement. Similarly, when adhesion forces 
are high, cell movement may be slowed or impaired (Palecek et al., 1997). 
 
Migration and adhesion represents the interaction between the actin cytoskeleton 
and the ECM. This occurs through focal complexes and adhesions, the “molecular 
clutch” of the cell. These are specialized cellular domains that connect the cell to 
its extracellular milieu, providing continuity between the extracellular matrix and 
actin filaments (Izzard & Lochner, 1976). Actin filaments undergo changes that 
enable formation of lamellipodia and formation of focal adhesions (Pollard & 
Borisy, 2003; Webb et al., 2004). 
 
More than 100 actin binding proteins have been described, which bind to actin 
filaments and variably sever, bundle, cross-link in order to regulate actin 
structure, function and remodeling (dos Remedios et al., 2003). Flii is a member 
of a subset of these actin remodeling proteins, the gelsolin family, which includes 
adseverin, Flii, villin, advillin, supervillain and CapG (Sun et al., 1995). 
 
Mohammad et al showed that Flii is a focal adhesion associated actin-capping 
protein that regulates cell migration (Mohammad et al., 2012). Flii associates with 





actin filaments and actin monomers, inhibiting actin polymerization and capping 
but not severing actin filaments. Cells with less expression of Flii are less adherent 
than wild type, with reduced numbers of focal adhesions containing activated 1 
integrins and vinculin and increased incorporation of actin monomers into new 
filaments at focal adhesions (Mohammad et al., 2012). In keeping with this, Flii 
knockdown enhanced cell migration, while overexpression reduced cell migration 
with increased numbers of focal adhesions (Kopecki et al., 2011). Kopecki showed 
that Flii inhibition of paxillin phosphorylation at Y118 site inhibits paxillin 
mediated focal adhesion disassembly. This also affects the Rac1-rhoA pathway, 
affecting adhesion and leading edge protrusion (Zvibel et al., 2008). 
 
Focal adhesions in fibroblasts are associated with stress fibre development and 
the transition from fibroblast to myofibroblast (Hinz, 2010). As Flii has is 
associated with stress fibre formation and increased focal adhesion complexes, 
this presents a possible mechanism via which Flii regulates the formation and 
function of myofibroblasts, the key cell in hypertrophic scarring. It is known that 
focal adhesions allow contractile activity of myofibroblasts to be transmitted to 
the ECM (Hinz et al., 2012), creating a more strained, stiffer environment. These 
mechanical conditions generated by the myofibroblast also lead to their sustained 
fibroproliferative activity (Hinz et al., 2001). Indeed, scar development in a murine 
model of hypertrophic was prevented by disruption of Focal Adhesion Kinase 
(FAK) signalling pathway (Wong et al., 2012). 
 
Chapter 6 focussed on this potential regulatory mechanism. Fibroblasts were 
cultured with bleomycin to induce a myofibroblast phenotype in a technique 





previously described by Yamamato (Yamamoto et al., 2000). By using bleomycin 
this provided a single cell insight into our murine model of hypertrophic scarring. 
 
As expected, fibroblasts cultured with bleomycin showed increased levels of 
αSMA and decreased motility, indicative of the myofibroblast phenotype. This was 
associated with an increase in Flii. Flii+/- mice showed increased motility and less 
αSMA expression, suggesting a partial restoration of normal fibroblast phenotype. 
Similar results were found when bleomycin treated cells were treated with FnAb. 
In future studies, image analysis and Western Blot protein analysis could be used 
to quantify immunocytochemical findings shown here, although time constraints 
did not permit this for this study. 
 
A role for Flii in the regulation of how fibroblasts sense and respond to mechanical 
ECM forces is compelling evidence that Flii may be an important regulator of 
hypertrophic scarring. Clinicians have long been aware that wound tension is one 
of the most important risk factors for hypertrophic scarring (Gurtner et al., 2008). 
Wong et al. recently demonstrated that focal adhesion kinase (FAK) is activated 
by cutaneous injury and that this process is potentiated by mechanical loading. 
FAK acts through extra-cellular related kinase (ERK) to mechanically trigger 
monocyte chemoattractant protein-1 (MCP-1) which is a potent chemoattractant 
and pro-inflammatory mediator. Blocking FAK was shown to block this affect and 
reduce scarring in a mouse model by uncoupling physical force from the molecular 
pathway of scar formation(Wong et al., 2011). The evidence prevented in this 
thesis suggests that Flii could function in a similar manner and treatment to 





reduce Flii activity could therefore interrupt the pathway between the physical 
stimuli for hypertrophic scarring and fibroproliferation (Figure 7.2). 
 
 
Figure 7.2 Schematic diagram summarizing potential mechanisms by which 
Flii may regulate the fibroproliferation underlying hypertrophic scarring 
 
7.4 FnAb and potential as a novel 
therapy 
 
Chapters 5 and 6 showed the efficacy of the FnAb monoclonal antibody therapy to 
reduce scarring and alter myofibroblast function in in vivo and in vitro 
respectively. Interestingly, Flii, like other gelsolin proteins is secreted in response 
to tissue injury and is likely to be a mediator of inflammation (Lin et al., 2011). 
Secretion of gelsolin family proteins into the circulation has been linked to 
functions in scavenging actin (Bucki et al., 2008) The FnAb has been shown to 
deplete Flii in conditioned media by over 90% (Lei et al., 2012). Thus, FnAb 





appears to “mop-up’ this extracellular to bring about improved wound healing. Flii 
secretion has been characterized (Lei et al., 2012) but Flii cell surface receptors 
have not yet been identified. However, FnAb has been shown to be taken up into 
cells (Kopecki et al., 2013) so its effects in this study may be explained by both 
intracellular and extracellular activity. Regardless, the FnAb has promise as a 
potential therapy in the clinical setting. 
 
7.5 Future directions 
 
This study is the first to identify a role for Flii in regulation of the fibroproliferation 
underlying hypertrophic scarring. Reducing Flii led to reduced scarring in an 
animal model of hypertrophic scarring, associated with significant changes in 
collagen-1:3 ratios, TGF expression and myofibroblast numbers. Flii exerts an 
effect on the fibroblast-myofibroblast transition, which may occur through its 
regulation of focal complex and focal adhesion dynamics. Further investigation of 
the details of this proposed mechanism would be of important regulator if 
hypertrophic scarring but it may also reveal other potential targets for novel 
therapies. 
 
Fibroproliferation underlies many other human pathologies. The role of Flii in 
other skin and soft tissue fibrotic conditions such as Dupuytren’s contracture or 
scleroderma is an area for further research. Fibroproliferative disease affecting 
other organs, such as cirrhosis, lung fibrosis and glomerulosclerosis would also be 
of interest. The success of many surgical procedures rely on wounds healing 





efficiently with a minimum of scarring. When this does not occur, complications 
can occur, such as bowel adhesions, tendon adhesions or stiff joints. Further 
studies into Flii as a target for therapies to improving would healing to suit a given 
clinical scenario could be of great benefit for many types of surgery. 
 
Investigation into hypertrophic scarring is hampered by the lack of suitable 
animal models. The bleomycin model validated by this study is useful for 
investigating the fibroproliferative process underlying hypertrophic scarring. 
However, further studies using larger animal models are necessary to confirm that 
these findings are applicable to the human milieu. 
 
The Flii neutralizing antibody presents a potential therapy to reduced or prevent 
the development of hypertrophic scarring. Further work is required to investigate 
the safety and efficacy of this antibody for use in human subjects. In addition, a 
suitable delivery system will need to be designed. 





7.6 Limitations of this study 
 
This thesis was successful in establishing and validating a novel model of hypertrophic 
scarring by using bleomycin to stimulate fibroproliferation in a murine milieu. The strength 
of this model was its focus on the fibroproliferative pathway that underlies hypertrophic 
scarring in the human setting. However, it has limitations. Firstly, it has been shown that the 
murine response to inflammation, including that at a genomic level, is significantly different 
to that seen in humans (Seok J, 2013). As inflammation is a key event in hypertrophic 
scarring  this presents a caveat for any conclusions drawn from a murine model. Secondly 
the model does not involve wounding of the epidermis/dermis as an initiation of the 
scarring process as would occur in the clinical setting. As mentioned, conclusions regarding 
the role of Flii in this study are limited to its role in the fibroproliferative process, rather 
than the entirety of hypertrophic scarring per se. 
 
This animal model enabled use of knockout Flii +/- and transgenic FliiTg/Tg  murine models to 
investigate the effects of altering Flii levels on fibroproliferation. Histology and 
immunohistochemistry performed on tissue from these models provided the majority of 
data for this thesis. While these techniques were suitable in providing information on the 
structural and cellular make up of the tissue, the results would  have been strengthened by 
the inclusion of different quantitative methods such as Western Blot protein analysis or PCR. 
Time limitations prevented this. 
 
Chapter 6 comprised of preliminary in vitro investigation of the effect of Flii on  fibroblast 
phenotype. Most of the data in this chapter was limited to qualitative immunohistochemistry 
and cell motility data. As above, these results would have been strengthened by the addition 




of Western Blot protein analysis and PCR. Furthermore more work is required to further 
elucidate the mechanism by which Flii exerts it effect on fibroproliferation and whether the 
myofibroblast is indeed the key cell in this regard. 
 
This thesis contained only a small amount of data derived from human samples. As detailed 
in this thesis, human skin represents an extremely unique wound healing environment. 
Indeed hypertrophic scarring is essentially a condition unique to humans. It is difficult to 
obtain human sample.  Samples which are obtained are extremely heterogenous making 
significant findings difficult to obtain. Biopsy of human skin at various stages of scar 
formation or systemic measurements of Flii would provide more information about the role 
of Flii in hypertrophic scarring. Ethical approval was not possible for these measurements in 
this study. Ultimately studies in the human milieu will be necessary if treatments targeting 
Flii are developed. 
 
7.7 Conclusions 
The aim of this study was to investigate the potential role of Flii in the formation 
of hypertrophic scars. Flii had been previously shown to be involved in the 
regulation of normal wound healing, with reductions in Flii leading to wounds that 
healed more quickly with smaller scars. For the first time this study showed that 
reducing Flii improves hypertrophic scarring, in terms of scar architecture, TGF 
expression, collagen-1:3 ratio and myofibroblast numbers. This involved the 
development of a novel murine model of hypertrophic scarring, which allowed 
targeted investigation of the fibroproliferative stage of scar formation. In vitro  
work showed that increasing Flii led to fibroblast expression of a myofibroblast 




phenotype, with increased αSMA and decreased motility. This effect may be due 
to Flii role in actin cytoskeletal regulation and its effect on how fibroblasts sense 
and respond to physical stimuli. Reducing Flii in both in vitro and in vivo conditions 
reduced scarring and myofibroblast expression respectively. This confirms Flii as 
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